,0,1
0,broker dealer prices,9.0
1,thermal solutions,9.0
2,fide executive,9.0
3,water absorbents,9.0
4,silicon holdings,9.0
5,tremendous attention,9.0
6,continuous progression,9.0
7,biomedical holdings,8.858760826115923
8,providing strategic operational,8.764705882352942
9,genome profiling,8.714285714285715
10,insider trading policies,8.666666666666666
11,managerial assistance,8.644705882352941
12,financial solution,8.623287671232877
13,undue reliance,8.5
14,office space,8.4375
15,enumeral biomedical,8.404215371570467
16,executive officer,8.390243902439025
17,currency translation,8.270833333333334
18,market maker,8.216710182767624
19,breakpoints,8.204878048780488
20,technological improvement,8.185185185185185
21,disruptive science,8.16025641025641
22,promissory note,8.14952966124735
23,accounting standards codification,8.126436781609195
24,accounting bulletin,8.126436781609195
25,vested forfeiture,8.120421245421246
26,performance productivity,8.114874815905743
27,negative covenant,8.098484848484848
28,pharma corporation,8.073643410852712
29,managerial assistance,8.028760330578512
30,financial officer,8.013531573671901
31,secured debt,8.005594405594406
32,cambrios technologies corporation,7.954146555506801
33,line basis,7.937662337662337
34,master netting arrangement,7.9375
35,line method,7.917757009345793
36,note thereto,7.914812680115274
37,actual award,7.905268490374873
38,average rate,7.902261048304213
39,minimum liquidity requirement,7.89317438055166
40,rise,7.85
41,home run return,7.8375
42,scenario,7.825
43,lending standard,7.814814814814815
44,converged standard,7.814814814814815
45,firm offer,7.791666666666666
46,weighted average based,7.790592334494773
47,reporting purpose,7.789954337899543
48,credit agency downgrade,7.761904761904762
49,biotechnology company,7.7550807712350185
50,retrospective approach,7.75079365079365
51,le meeting,7.7094400177069495
52,eleven month,7.689563011763103
53,forfeiture,7.685897435897436
54,local tax,7.685314685314685
55,affiliated company,7.683652199806447
56,bid quotation,7.68
57,unaudited note,7.678277793168402
58,contour energy systems,7.66777108433735
59,normal recurring accrual,7.666666666666666
60,income taxes,7.666589683599595
61,march,7.665354330708661
62,operating officer,7.664580185624866
63,corporate capital,7.662948018039401
64,lodo therapeutics corporation,7.656976744186046
65,equity method investees,7.653283325135268
66,subsequent events,7.6329079182105115
67,business multiples,7.625448028673835
68,microeconomic event,7.625
69,unfunded commitment,7.617687074829933
70,intensive sector,7.595754342150073
71,currency rate,7.587380095923262
72,lattice model,7.586345381526105
73,traded stock,7.581694033792884
74,generally coincides,7.576271186440678
75,bridge note,7.573258474806671
76,laser light engines,7.571428571428571
77,preceding round leading,7.552757793764988
78,cobalt technologies,7.550416564567508
79,option theory,7.543678160919541
80,mailing date,7.518518518518519
81,adesto technologies,7.5176243567753005
82,proposed valuation,7.5058419243986245
83,adjusted basis,7.504329004329003
84,accrued benefit,7.496491228070175
85,adesto technologies,7.495659744206661
86,china electronics corporation,7.49299824956239
87,month,7.490533442018124
88,month,7.474941596714422
89,common stock,7.472274881516588
90,method,7.467757009345794
91,managerial assistance,7.452815533980583
92,venture capital firm,7.450204915370925
93,wa,7.440983405470762
94,loss relate,7.4381520119225035
95,quoted price,7.437304333498105
96,income approach,7.422570654277971
97,contractual obligations,7.421722113502936
98,liquidity events,7.419623655913979
99,contractual obligations,7.406130268199234
100,employee bonus expense,7.404379422451711
101,market index,7.398528364585806
102,secondary liquidity,7.393113588799884
103,compensation cost,7.390652557319224
104,data communication metrology,7.383333333333333
105,adesto technologies corporation,7.379146555506801
106,milestone milestones,7.377029935433379
107,preferred equity,7.373825386473788
108,secondary liquidity,7.369623655913978
109,valuation committee book,7.365960972017673
110,valuation committee,7.365960972017673
111,valuation committee,7.365960972017673
112,audit committee valuation,7.365960972017673
113,backed company,7.36430736553624
114,venture debt deal,7.360741745816373
115,preferred stock,7.360573952200902
116,year nqsos,7.355102040816327
117,tax saving,7.343445287107259
118,exemptive order,7.340659340659341
119,capital market,7.33420365535248
120,loan facility,7.32792187348639
121,cash,7.32653791130186
122,net asset,7.323741610738255
123,forfeiture rate,7.318997742982084
124,existing privately held,7.314705357673782
125,asu wa adopted,7.311951471347444
126,interest rate,7.3050963809105385
127,interest rate,7.3050963809105385
128,unaudited notes,7.304438162885651
129,fee income,7.302832904105438
130,asset,7.297352721849366
131,held portfolio,7.290202046415505
132,unaudited notes,7.28884631758195
133,product,7.28125
134,investment amounts,7.275222858492237
135,accounting policies,7.275197112187708
136,additional meeting,7.266560518489422
137,traded companies,7.259419152276296
138,cash flow,7.25602509078904
139,discount rate,7.255940701983867
140,commitment fee,7.24874297545105
141,valuation committee meeting,7.240960972017673
142,goal,7.238095238095238
143,stock award,7.235849019731994
144,stock price,7.235769691205169
145,month,7.23416565922385
146,additional capital,7.230169528922884
147,compensation expense net,7.224419104991394
148,macroeconomic event,7.212765957446809
149,compensation committee doe,7.205357142857142
150,equity incentive plan,7.195741369552915
151,cash reserve,7.188755706786587
152,fee,7.1873059006211175
153,cash flows,7.181476182906797
154,pricing service,7.178733123130407
155,office space,7.173349056603774
156,comprehensive loss,7.154201394638553
157,basic approach,7.15079365079365
158,market data,7.150043516100957
159,debt,7.143976348854398
160,unrealized appreciation,7.143893861892583
161,focused portfolio,7.142601951899618
162,stock rights,7.138941548183254
163,debt issuance cost,7.138920955587622
164,based award,7.136149045421027
165,secured debt,7.1332539800624915
166,corporate headquarters,7.116883116883116
167,sublease income,7.1155270034843205
168,note debt,7.113269980390756
169,lower cost,7.104938271604938
170,disruptive technology,7.102564102564102
171,capital loss carryforward,7.101100029961906
172,capital loss carryforwards,7.101100029961906
173,compensation benefit expense,7.100076999728236
174,debt investment,7.0975030658470715
175,accounting policy,7.096807151979565
176,guidance,7.092455450127285
177,growth potential,7.091666666666667
178,intercompany account,7.087535840782594
179,invested capital,7.087190442281826
180,quot salaries,7.084691818040676
181,venture capital portfolio,7.084034937445981
182,quot note commitments,7.083013270085775
183,financial liability,7.082546930492136
184,secondary liquidity,7.074501704694466
185,custody fee,7.073609092110479
186,financial statement,7.071176260630899
187,financial statements,7.0670294367137725
188,precision medicine market,7.065319020738164
189,based compensation,7.0628672160113615
190,debt investment,7.061175270859744
191,settlement procedure,7.054166666666667
192,projected market,7.050043516100958
193,exercise price,7.049858446052218
194,pocketed investor,7.048913043478261
195,income tax,7.048000779708096
196,debt expense,7.040713109728796
197,stock exchange,7.037751071992779
198,statement statements,7.034379723834364
199,valuation committee,7.032627638684339
200,tradable share,7.029875797247398
201,operating company,7.029417054420859
202,debt expense quot,7.025769045611247
203,public information,7.022634508348793
204,adesto technologies,7.019788858939802
205,learning technology,7.019230769230769
206,traded company,7.014499923511314
207,liquidity doe,7.01248079877112
208,financial statement,7.011652451107091
209,consolidated statements,7.011157495817976
210,investment income taxes,7.008538323515019
211,operating expense,7.007359284281131
212,option pricing model,7.003833066255169
213,ten investment,6.997630885248089
214,traded investment,6.996180472306994
215,common stock,6.995764814402494
216,quot wa formed,6.986049497215382
217,milestone payments,6.970012391573729
218,stock liquidity,6.9680613281282415
219,borrowing capacity,6.958333333333334
220,income tax,6.957091688799006
221,preferred stock,6.955856971068826
222,investment commitment,6.954448394860631
223,portfolio,6.953274466519499
224,unamortized fee,6.952778014124053
225,contributing factor,6.952367713835605
226,market quotation,6.950043516100958
227,debt security,6.949843365845828
228,custody fee,6.9477225672877845
229,wa originally structured,6.944542564464854
230,related sector,6.943737060041407
231,business environment,6.941218301761182
232,unamortized fee,6.937186168820352
233,financial statement,6.932666943860713
234,portfolio company,6.930577459976741
235,portfolio company,6.930577459976741
236,interest bearing account,6.927325128524692
237,liquidity scenario,6.919623655913979
238,financial information,6.914103997763489
239,portfolio investment,6.912258008772421
240,restricted security,6.906931077393796
241,quot funds,6.90433995408268
242,common stock,6.90409306333477
243,ascertainable market,6.9009207090834135
244,operating commitment,6.8920233580157735
245,closed trading,6.888941548183254
246,realized gain,6.888354203895689
247,operating expense,6.885064911986759
248,income quot,6.881189714666943
249,month period,6.87659936779095
250,accounting policy,6.875197112187708
251,owned subsidiary,6.874692874692874
252,held company,6.869786128908801
253,potential contribution,6.866666666666667
254,valuation firm,6.864712892140561
255,loan facility,6.86001395690993
256,additional capital,6.855169528922884
257,market expectation,6.853889669947112
258,significant estimate,6.853888535706718
259,held investment,6.851466677704481
260,traded security,6.848520772305751
261,venture capital industry,6.846038248704259
262,large round,6.844424460431655
263,service period,6.841450641529196
264,substantial risk,6.8344370860927155
265,liquidity,6.827956989247312
266,compensation expense,6.827395295467585
267,advisory service,6.824480618276312
268,stock price,6.821483976919454
269,lender party thereto,6.821428571428571
270,risky company,6.810636326790574
271,stock basis,6.809937219178925
272,financial asset,6.809529281971132
273,bridge,6.807091111995207
274,income tax expense,6.80375105353066
275,market approach,6.799322015379456
276,market quotation,6.798528364585806
277,hierarchical level,6.7863945578231295
278,cost basis,6.778314894981561
279,gains,6.77723753463522
280,net asset,6.774722002895118
281,unrealized depreciation,6.763490871967331
282,proceeds,6.762151409375821
283,september valuation methodologies,6.760897371234894
284,low valuation,6.759175257731958
285,federal state,6.754905375595031
286,debt amortization,6.750223935526529
287,option,6.749738766980148
288,june valuation methodologies,6.745305525931192
289,investment group,6.744114261207169
290,interest,6.743630389555629
291,investment partners,6.741369614961575
292,early adoption,6.738235294117647
293,debt,6.738175230566536
294,traded share,6.733739393968139
295,item management,6.731271751019191
296,enhancing fee,6.729169108168287
297,distribution requirement,6.727682377298745
298,holding period,6.725159914712154
299,focused company,6.722186034392914
300,change merger,6.720657276995306
301,unaffiliated company,6.71661923277348
302,write ups,6.7154750011892865
303,equity,6.703866583188594
304,held security,6.703806977703238
305,precision health,6.7035241928858955
306,liquidity event,6.702956989247312
307,net gain,6.700096628138113
308,gain,6.700096628138113
309,net income,6.699277003484321
310,low yield,6.69811320754717
311,capital gain,6.696482834286984
312,commitments,6.681877356732189
313,scenario,6.681818181818182
314,realized loss,6.680471399570611
315,write ups,6.67817896389325
316,stock price appreciation,6.6769461617934045
317,business volatility,6.673835125448029
318,term appreciation,6.673506438201114
319,recycled approximately million,6.667705088265835
320,period,6.6668513062488834
321,venture capital company,6.6636190199392775
322,stage company,6.652808043962292
323,period,6.651259460945181
324,operating loss,6.6454428405628905
325,venture capital investment,6.645299568734957
326,debt obligation,6.6402097902097905
327,sector industry,6.633152173913043
328,transformative company,6.6300807712350185
329,agency security,6.629890844085612
330,life science energy,6.629700854700856
331,similar security,6.626138657066491
332,energy company,6.6110331521873995
333,performance target,6.606216807247735
334,associate meet,6.603850050658561
335,precision medicine company,6.603689609205558
336,item management,6.603000239062874
337,financial asset,6.600345608501744
338,cash expense net,6.598576063912302
339,common stock,6.597274881516588
340,stock option,6.590953042436128
341,stock option,6.590953042436128
342,enhancing fees,6.587002096436059
343,quot,6.5856364874064
344,tax benefit,6.585593792172739
345,distributable income,6.577965928565754
346,based approach,6.572381882341762
347,employee stock option,6.569127645610731
348,related innovation,6.567399267399267
349,management depth,6.562118780096308
350,stock,6.5618264523838645
351,phylagen,6.561241610738255
352,material energy,6.560585585585585
353,treasury share,6.557653575025176
354,electronics company,6.555387990897077
355,hybrid approach,6.550793650793651
356,pre emptive,6.55018315018315
357,asset liquidity,6.549912885699852
358,stock,6.546234607080163
359,percent income test,6.539391406306776
360,stock,6.538571177812884
361,net realization,6.534868421052632
362,partner company,6.532858549012796
363,stock price,6.532065987501465
364,future amount,6.530878069080316
365,option exercise pattern,6.530041797283177
366,market interest rate,6.521806563678163
367,business strategy,6.515405293631101
368,investment diversification requirement,6.508875263059184
369,valuation committee doe,6.508818114874815
370,remaining fund,6.505415074396293
371,net loss,6.492213823813035
372,operating expense,6.4922077691296165
373,investment company,6.491842091265717
374,net asset,6.4904082774049225
375,health care cost,6.490073406740073
376,hybrid approach,6.487035261531906
377,net assets,6.4764307386482525
378,cash flow,6.470310805074753
379,portfolio investment factors,6.467813564327976
380,service company,6.466087740713509
381,frequency,6.445632798573975
382,diversification test,6.442074417336786
383,early adoption,6.436516853932584
384,investment advisers,6.43600944033145
385,offering price,6.435233940123364
386,bridge,6.433926109059211
387,income,6.433107774719339
388,portfolio company,6.430577459976741
389,service period,6.427164927243482
390,investment,6.426917919583271
391,preceding financing,6.422127163134357
392,subsequently declared worthless,6.41764705882353
393,interest rate,6.417455931472336
394,actual result,6.407333369351846
395,portfolio company,6.404261670503056
396,stock price,6.402436357871835
397,period,6.402221276169488
398,meaningful growth,6.4
399,regulatory requirement,6.398550724637681
400,enhanced disclosure,6.395644283121597
401,equity method investment,6.3900446451659665
402,performance risk,6.388465341151898
403,relevant information,6.384566326530612
404,fasb issued asu,6.381054131054131
405,financing requirement,6.380279644568848
406,qualifying asset,6.372982973950206
407,cash flow,6.368384641350836
408,investor,6.361413043478261
409,insurance expense,6.360728628800918
410,milestone payment,6.357441381861434
411,significant estimate,6.353888535706718
412,stock plan,6.352301256034746
413,statement,6.347960739470173
414,unrealized appreciation,6.345495481922038
415,expectation estimate,6.342307692307693
416,price market volume,6.3407313082456795
417,withholding tax,6.339522546419098
418,event,6.335664335664335
419,life science portfolio,6.330197543442576
420,term potential,6.3239966342795455
421,net asset,6.323741610738255
422,demand note,6.319812680115273
423,york corporation accelerator,6.316658577918513
424,company precision health,6.315747821263771
425,option price model,6.310185018800892
426,potential sale,6.309166666666667
427,accelerator corporation,6.306648567908503
428,milestone payment,6.30646098970457
429,undx consortium,6.305882352941176
430,dividend rate,6.304918855613184
431,sufficient capital,6.303207758299142
432,operating expense,6.302813829735677
433,gross proceeds,6.298096472629466
434,similar business,6.297089819718611
435,revenue cash flow,6.296025090789039
436,tax treatment,6.2959866220735785
437,capital,6.290894145985529
438,stock option,6.290128866611952
439,volatility,6.289771237990221
440,portfolio security,6.286337439205959
441,bank kovio,6.2857142857142865
442,level investment,6.282679687377637
443,asset base,6.276758852117565
444,based award,6.274942971323394
445,fair valuation,6.2699444885011895
446,percent,6.266222198463731
447,capitalization company,6.266052558068874
448,illiquid security,6.265157958057624
449,leasehold improvement,6.263973063973063
450,quoted price,6.261480157673929
451,loan facility,6.253190690690691
452,financial statement,6.249457329155872
453,quarter,6.2417912916366305
454,additional capital,6.230169528922884
455,valuation,6.227106292214717
456,lower valuation,6.2271062922147165
457,quarter,6.226199446332928
458,wa,6.225814007709778
459,molecular imprints,6.224634698497634
460,future event,6.223470661672909
461,cash premium,6.220448167712116
462,benefit,6.217456910589279
463,market,6.2100759501272
464,portfolio company,6.209461922128135
465,future growth,6.204026217228464
466,financing charge,6.202702702702703
467,equity method,6.200158325135268
468,milestone,6.19964202120336
469,price,6.19228268847646
470,historical data,6.18941798941799
471,portfolio day,6.181653878165843
472,dividend interest gain,6.180038980022738
473,impactful company,6.178157694311942
474,tax,6.172296677069947
475,portfolio company,6.167756947156228
476,interest entity,6.161626541397534
477,unrealized depreciation,6.1542335497915985
478,investment pace,6.150411395445479
479,investment,6.148979115515426
480,warrant coverage,6.147823629169022
481,payment,6.140815799556866
482,remaining principal outstanding,6.140384615384615
483,company,6.135713561263781
484,amendment,6.127365901878154
485,net proceeds,6.121945980643887
486,call option,6.1181462460259235
487,readily determinable fair,6.11497975708502
488,stage investor,6.1133069828722
489,portfolio company,6.106633798004909
490,financial asset,6.106404281971132
491,market transaction,6.105419860186979
492,benefit,6.102125030887077
493,portfolio company,6.100388780731457
494,quot,6.0972989843714895
495,life science industry,6.092200854700855
496,investments quot,6.090674816774625
497,unrealized change,6.09004133496632
498,investor ariel investments,6.089720603615718
499,series seed financing,6.085681426106958
500,commencing operation,6.085074891954295
501,valuation,6.084789292819678
502,based payments,6.0791982904723305
503,proposed valuation,6.078657458379207
504,company exit,6.064698689548589
505,loan facility,6.063796751296752
506,year,6.061588172782704
507,wa percent,6.055926470095713
508,additionally income,6.055450472872076
509,discount rate assumption,6.051395247438412
510,market,6.043941304049088
511,multiple exit,6.040565001683196
512,company,6.026786903596888
513,quot transaction,6.022148362627952
514,debt liability,6.01943241943242
515,milestone payment,6.018820540266368
516,exit environment,6.017263224580297
517,future payment,6.015474815359305
518,indemnity claim,6.009411764705883
519,share award term,6.009291441879923
520,act quot,6.008982633575089
521,amount,6.0070844099913865
522,option holder,6.002373813093453
523,quot,5.980449167521673
524,influence,5.975870885266858
525,based input,5.9756422856021665
526,conversion ratio,5.961503811503812
527,financing,5.957783473937721
528,marketable asset,5.953785470387379
529,exited company,5.949525215679463
530,general annually derive,5.945324096981693
531,based share,5.936930249235218
532,york corporation,5.9355052727145745
533,interest method,5.934213604410591
534,discus portfolio company,5.930577459976741
535,fund,5.929590898572117
536,management,5.929571915196502
537,discussion rent expense,5.926204819277109
538,stock price,5.924294281369104
539,realized return,5.91315272098144
540,gain,5.912596628138114
541,portfolio investment,5.912258008772421
542,life science company,5.9097816259358735
543,escrow period,5.9075192220714605
544,probability,5.904371584699453
545,common share,5.903204703843237
546,unobservable input,5.902814384632567
547,program doe,5.898901098901099
548,america gaap applicable,5.898550724637682
549,based share,5.895908473239955
550,net asset,5.895170182166826
551,loan facility,5.89207957957958
552,company discount,5.8867824029366504
553,leap proceeds,5.88602027156244
554,market sale,5.8842101827676245
555,directors,5.881475822652293
556,harris partners,5.879227274813013
557,portfolio company,5.877945881029372
558,september,5.876021129355372
559,september primarily owing,5.8760211293553715
560,business plan,5.875562072336265
561,revenue code,5.872923832923832
562,june,5.860429284051671
563,june,5.86042928405167
564,enumeral biomedical,5.8587608261159225
565,october senova systems,5.857606249172514
566,operation expense,5.856842911685369
567,investment,5.8507302779020955
568,portfolio company,5.847244126643407
569,term effect,5.842086065173854
570,year beginning,5.838254366073915
571,valuation committee,5.834710972017673
572,volatility assumption,5.832213735251994
573,premium,5.829215346586948
574,imprints proceeds,5.828803586438778
575,operating result,5.82615771715571
576,financial position,5.8127495546409484
577,initial investment,5.8123915721315385
578,total investment,5.81041879463157
579,investment commitment distribution,5.8073895713312185
580,program purchase,5.80683409010676
581,return,5.802357266435986
582,sale price,5.797661476355247
583,equity security,5.796968361350844
584,concentration,5.7885697051358385
585,investee company,5.7872285140530755
586,valuation committee,5.78701360359662
587,current period,5.782577497129736
588,quoted price,5.774513635823686
589,stock option increase,5.772141967517562
590,sector decrease,5.758455453440783
591,prior period,5.749101713653952
592,portfolio company,5.748759278158558
593,increase wa offset,5.746345524634006
594,undisclosed buyer,5.745881705134677
595,interest rate,5.74455826431861
596,time cash,5.742601860632742
597,agency security change,5.738330325596189
598,board member,5.737359339834958
599,operation expense,5.729584782420014
600,term assumption,5.723053157814817
601,regulatory approval,5.722222222222222
602,sec certification,5.72050787528126
603,sale price,5.716709095402867
604,impactful return,5.715122377622377
605,period amount,5.709286898839138
606,portfolio company,5.705577459976739
607,outstanding class,5.699074074074074
608,september,5.6977784515311045
609,underlying security,5.696244477172312
610,stage company,5.694474710628958
611,investment portfolio,5.690500686596688
612,portfolio company,5.689613604555053
613,additional payment,5.688606855116118
614,total investment,5.683160665366214
615,based payment,5.682313555269839
616,june,5.682186606227403
617,term income,5.672541984359799
618,total asset,5.66767397148096
619,portfolio company investment,5.667338780007438
620,cash distribution,5.666658574951935
621,ric income,5.661260069437975
622,development product development,5.65625
623,escrow payment,5.6549268590004065
624,security law,5.654319011333802
625,net asset,5.652412939409584
626,amendment date,5.645400238948627
627,management,5.6411103767349635
628,invested capital,5.64103659612798
629,invested approximately million,5.637402057962806
630,discount factor,5.635129396597287
631,time employee,5.630354090354091
632,multiple source,5.625910013128058
633,venture,5.609226594301221
634,investment portfolio,5.599758008772421
635,gain,5.599113482070698
636,related milestone,5.596524618085956
637,part time employee,5.586845318424266
638,management fee,5.579102186047916
639,securities exchange act,5.563533834586466
640,taxable year,5.561916147212023
641,cash expense,5.548285366237883
642,act,5.540225189094371
643,fee payment,5.534171165418625
644,investee company,5.522522631700134
645,biology investment,5.519618462887841
646,period presentation,5.514720354272593
647,valuation committee,5.508818114874815
648,assumption,5.491190002657893
649,proceeds,5.4895267518789055
650,portfolio company,5.47745245997674
651,approximately percent,5.475399092513932
652,exchange commission sec,5.46890756302521
653,liquidation preference redemption,5.465437788018433
654,approximately percent,5.459807247210231
655,consolidation guidance,5.453203827950278
656,trade date concentration,5.446548821548822
657,payment,5.424757055842283
658,additionally synglyco entered,5.418045112781955
659,exit opportunity,5.418006993006993
660,control,5.4091211752754225
661,payment,5.3896912759551086
662,deal team,5.365079365079366
663,venture debt,5.360741745816373
664,september directors fee,5.356139358661869
665,investments quot,5.348917494598893
666,portfolio company investments,5.346385020114197
667,additional repayment,5.343405041339772
668,june directors fee,5.3405475133581675
669,july bridgelux,5.339516129032258
670,convertible debt,5.324413950829046
671,unrestricted security,5.321244477172312
672,form model,5.316946474422279
673,level investment,5.310922365201905
674,security,5.293979668809943
675,valuation procedures,5.286232817869416
676,investment company subsidiary,5.275625875049501
677,foreign currency,5.270833333333334
678,series,5.269069850502577
679,greater return,5.26325671045117
680,publicly traded,5.259419152276296
681,traded publicly,5.259419152276296
682,investment opportunity,5.255615015354982
683,owned subsidiary,5.249692874692874
684,portfolio company,5.236766385058173
685,portfolio company,5.233607763007043
686,approximately percent,5.219031309719658
687,july synglyco,5.193087557603686
688,investment company,5.191090211566468
689,total amount,5.16732591267475
690,disruptive science,5.160256410256411
691,dollar amount,5.155698005698006
692,unobservable input,5.154054054054054
693,unrestricted security,5.145492597473064
694,privately held,5.114705357673783
695,liability level inputs,5.1013314727600445
696,portfolio company ability,5.077636283506152
697,market,5.073853039910482
698,input assumption,5.073646530543082
699,compensation committee,5.0625
700,share class,5.049568660842701
701,additional repayment,5.039636996318974
702,enumeral owned,5.038277511961722
703,forfeiture rate,5.024880095923262
704,secondary sector,5.019927536231884
705,accrual basis,5.004329004329004
706,percent percent,4.995204425311712
707,adesto technologies,4.972169811320755
708,accompanying note,4.962228410452353
709,adesto,4.948489932885906
710,investee company investments,4.938330191837592
711,salaries,4.9298245614035086
712,commitments,4.9281460134486075
713,company,4.926578355776081
714,binomial model,4.919678714859438
715,lattice model,4.919678714859438
716,venture capital,4.908538248704259
717,increase decrease,4.893075428148919
718,financial performance,4.881019629995763
719,classification,4.875
720,current environment,4.871325828642902
721,debt expense,4.870901788974079
722,secondary liquidity,4.869623655913978
723,sale classification change,4.854823943661972
724,service,4.852425180598555
725,market environment,4.850856524231039
726,precision medicine,4.84860883797054
727,gross income,4.847534579241897
728,compensation expense,4.836919104991394
729,wa formed,4.831182240578213
730,cobalt biofuels,4.821428571428571
731,bridge note,4.818541493674596
732,company,4.785445143704655
733,positive contribution,4.775
734,diversification requirement,4.772113943028486
735,market capitalization,4.762164728222169
736,financial statement,4.761652451107091
737,national exchange,4.757142857142857
738,unrealized appreciation,4.756393861892583
739,funds,4.749472697445512
740,future environment,4.746505892025212
741,capital,4.742493472584856
742,ownership impact,4.735724405730178
743,remaining capacity,4.733333333333333
744,tax,4.730769230769231
745,prepaid expense,4.7297762478485375
746,derivatives,4.728146013448607
747,accounting policy,4.726436781609196
748,comprehensive income,4.726322458029776
749,net basis,4.725162337662338
750,internal model,4.707557502738226
751,science,4.701923076923077
752,outstanding debt,4.69469696969697
753,debt,4.69469696969697
754,investment series,4.691168614863525
755,local tax,4.685314685314685
756,respective market,4.675043516100958
757,open market,4.666710182767624
758,labs,4.666666666666667
759,proposed modification,4.666666666666666
760,biomedical application,4.661392405063291
761,net income,4.659277003484321
762,statement,4.658364779874214
763,treasury stock,4.655608214849922
764,equity method,4.653283325135268
765,employee director,4.652606421356422
766,energy portfolio,4.650496688741722
767,general office,4.650265957446809
768,annual basis,4.647186147186147
769,fully vested,4.642857142857142
770,stock,4.6401043388809295
771,september unaudited,4.637771496218985
772,global environment,4.634146341463415
773,unaffiliated rights,4.628205128205128
774,similar business,4.625448028673835
775,june,4.6221796509152835
776,preferred equity,4.619108405341713
777,market quotation,4.6167101827676245
778,estimated rate,4.610664409648751
779,multiple sector,4.609839816933638
780,preferred stock,4.605856971068826
781,round led,4.601777401608125
782,stock,4.601159343667982
783,federal tax,4.601139601139601
784,extended modified,4.6
785,undx consortium,4.6
786,actively traded,4.596153846153847
787,electronics portfolio,4.594851527451399
788,escrow,4.585977564102564
789,item management,4.576404494382023
790,operating expense,4.5755411024629495
791,timing difference,4.5726783020900665
792,statement,4.570182961692396
793,business,4.56989247311828
794,capital,4.568473864741719
795,eligibility requirement,4.565217391304348
796,corporation quot,4.561844000823214
797,information,4.560816326530612
798,precision health,4.560667050028752
799,financial asset,4.559529281971132
800,average holding,4.557142857142857
801,similar expression,4.555555555555555
802,freely tradeable,4.555555555555555
803,current rate,4.553726249769415
804,equity market,4.552236498557098
805,hybrid approach,4.550793650793651
806,senova systems,4.549913941480207
807,volatility,4.548387096774194
808,laird technologies,4.547169811320755
809,level,4.545918367346939
810,corporate bond,4.545454545454545
811,call option,4.543678160919541
812,federal state,4.542784163473819
813,firm,4.541666666666666
814,bank account,4.538775510204082
815,employee,4.5349927849927845
816,directors,4.534130575307046
817,independent member,4.533870967741935
818,indemnity claim,4.529411764705882
819,wa terminated,4.523489932885906
820,wa approved,4.523489932885906
821,public equity,4.517344497607656
822,debt discount,4.50909090909091
823,share purchase agreement,4.5070709628864805
824,income tax,4.502546234253551
825,harris partners,4.500848896434635
826,preventative care,4.5
827,average price,4.499209095402867
828,accrued benefit,4.496491228070175
829,officer employee,4.4934185056136275
830,operating commitment,4.492023358015773
831,similar asset,4.491797166293811
832,market income,4.488487186251945
833,sec,4.483193277310924
834,option,4.477011494252874
835,income,4.4766550522648085
836,financial condition,4.473287671232876
837,common stock,4.472274881516588
838,expense,4.471016140031826
839,stock option,4.465953042436128
840,cash flows,4.465426800190748
841,venture investor,4.464957819597664
842,outstanding equity,4.460526315789474
843,respective location,4.458333333333334
844,categorized based,4.454878048780488
845,current market,4.453889669947111
846,insurance expense,4.444061962134251
847,consolidated statements,4.443741765480896
848,foreign company,4.4425807712350185
849,valuation policy,4.439175257731959
850,public exchange,4.438961038961039
851,contractual arrangement,4.4375
852,quoted price,4.437304333498105
853,principally engaged,4.430769230769231
854,consummated arm,4.428571428571429
855,performance target,4.4243986254295535
856,regenerative medicine,4.423076923076923
857,income approach,4.422570654277971
858,option,4.4225626230709345
859,exit environment,4.422025129342202
860,potential liquidity,4.419623655913979
861,amount,4.4185185185185185
862,diversification strategy,4.415229885057471
863,ha capital,4.413789768881152
864,forfeiture estimate,4.413461538461538
865,gross return,4.413257575757576
866,current portfolio,4.412676175921209
867,historical information,4.411186696900982
868,amendment doe,4.40952380952381
869,primary liquidity,4.408765070055393
870,meaningful growth,4.4
871,public market,4.398528364585806
872,interest,4.394799618320611
873,option holder,4.39367816091954
874,covenant,4.390804597701149
875,compensation cost,4.390652557319224
876,risk factors,4.389992641648271
877,independent milestone,4.387216692648998
878,additional operating,4.387012339523869
879,march unaudited,4.381403713424711
880,portfolio,4.38037473752221
881,york corporation,4.379949717159019
882,unrealized depreciation,4.375990871967331
883,existing portfolio,4.3754966887417215
884,base rent,4.375
885,historical fluctuation,4.37037037037037
886,future performance,4.370091509324684
887,market approach,4.367503833561274
888,valuation committee,4.365960972017673
889,january management,4.360856212876294
890,concentration,4.358333333333333
891,agency security,4.351006381934217
892,agbiome llc,4.350649350649351
893,expense,4.34375801076647
894,option,4.3436781609195405
895,statement,4.343242828654702
896,current employee,4.34035409035409
897,discount ratio,4.33939393939394
898,consistent basis,4.337662337662337
899,corporate structure,4.337121212121212
900,applicable income,4.336994394788668
901,loan facility,4.336524024024024
902,public listing,4.335664335664335
903,equity offering,4.335526315789474
904,customary exclusion,4.333333333333334
905,healthcare decision,4.333333333333334
906,biosystems,4.333333333333333
907,month period,4.331144822336405
908,gross write,4.330859616573902
909,liquidity event,4.327956989247312
910,daily liquidity,4.327956989247312
911,adequate liquidity,4.327956989247312
912,large fund,4.326530612244898
913,appropriately represent,4.325
914,net asset,4.323741610738255
915,stock,4.322274881516588
916,leasehold improvement,4.318518518518518
917,alternative method,4.317757009345794
918,previously authorized,4.3151515151515145
919,gain,4.312596628138113
920,quot quot,4.3097345132743365
921,business,4.307071960297767
922,debt investment,4.306458289727669
923,interest rate,4.3050963809105385
924,milestone payments,4.303345724907063
925,remaining milestone,4.303345724907063
926,expense,4.301204819277109
927,unrealized loss,4.298823948681397
928,address electronics,4.298142717497557
929,net cash,4.297371244635193
930,cash net,4.297371244635193
931,asset,4.297352721849366
932,standard issued,4.296296296296296
933,expense,4.291681009753299
934,interest expense,4.289754437597719
935,expense interest,4.289754437597719
936,square foot,4.285714285714286
937,recent arm,4.279999999999999
938,company,4.278570704120924
939,business strategy,4.278225806451613
940,completely exited,4.277777777777778
941,partially exited,4.277777777777778
942,fully exited,4.277777777777778
943,operating activity,4.274336283185841
944,stage classification,4.272727272727273
945,income,4.2717770034843205
946,taxable income,4.2717770034843205
947,outstanding option,4.26867816091954
948,agreement,4.268346111719605
949,payment,4.267821147150449
950,liquidity discount,4.267350928641251
951,accomplishment,4.265151515151515
952,medical benefit,4.2631578947368425
953,core benefit,4.2631578947368425
954,remains difficult,4.261904761904762
955,interest income,4.260326621804931
956,otc exchange,4.257142857142857
957,payments,4.257142857142857
958,cash flow,4.25602509078904
959,discount rate,4.255940701983867
960,necessarily represent,4.255232558139535
961,company place,4.2550807712350185
962,risky company,4.2550807712350185
963,net,4.254166666666666
964,complex model,4.253012048192771
965,mersana therapeutics,4.25
966,bdcs,4.25
967,frequent communication,4.25
968,perform interim,4.25
969,potentially dominant,4.25
970,receivable totaling,4.25
971,financial institution,4.248287671232877
972,business,4.245948811146448
973,capital,4.238600739020843
974,aggregate operating,4.237639035479419
975,current status,4.237179487179487
976,stock price,4.235769691205169
977,long term,4.232329967612879
978,employment tax,4.230769230769231
979,tax authority,4.230769230769231
980,actively engaged,4.230769230769231
981,include earned,4.230425824175824
982,additional capital,4.230169528922884
983,income,4.226322458029776
984,private financing,4.224441833137485
985,fixed asset,4.22195589645254
986,accrued interest,4.221882951653944
987,market participant,4.216710182767624
988,market inefficiency,4.216710182767624
989,otc market,4.216710182767624
990,market comparables,4.216710182767624
991,advantageous market,4.216710182767624
992,exciting market,4.216710182767624
993,growing market,4.216710182767624
994,gas market,4.216710182767624
995,general supervision,4.212765957446809
996,general economy,4.212765957446809
997,doe business,4.212749615975422
998,applicable doe,4.20807453416149
999,diversification,4.206896551724138
1000,entirety,4.204878048780488
1001,historical fact,4.203703703703703
1002,financing charge,4.202702702702703
1003,financing,4.202702702702703
1004,credit facility,4.201388888888889
1005,ventures,4.200909287724616
1006,interest,4.2006708304418225
1007,historically held,4.198884462151394
1008,consolidated schedule,4.197610237434475
1009,cost basis,4.192600609267275
1010,deferred gain,4.191489361702128
1011,potentially lead,4.1875
1012,liabilities,4.186637618010167
1013,remaining year,4.183673469387755
1014,stock plan,4.182489935280029
1015,public offering,4.181818181818182
1016,aggregate commitment,4.1809898271235095
1017,high volume,4.1782682512733444
1018,total operating,4.178182437031994
1019,expense recognition,4.176204819277109
1020,rely primarily,4.176056338028169
1021,portfolio companies,4.175496688741722
1022,larger portfolio,4.175496688741722
1023,award,4.168560214831646
1024,sufficient competition,4.166666666666667
1025,ii approaches,4.166666666666666
1026,target,4.166666666666666
1027,economic downturn,4.166666666666666
1028,probability,4.166666666666666
1029,target project,4.166666666666666
1030,liquid market,4.164078603820256
1031,company,4.1613307712350185
1032,debt security,4.158798589726425
1033,accounting fee,4.1574926822303135
1034,plan,4.156511350059737
1035,product,4.15625
1036,life science,4.154700854700855
1037,expired exercised,4.154150197628459
1038,fiscal year,4.154043839758126
1039,additional information,4.15349238286864
1040,employee member,4.1531746031746035
1041,remaining amount,4.151851851851852
1042,main approach,4.15079365079365
1043,current cash,4.14705073181468
1044,net proceeds,4.146536144578313
1045,similar security,4.14465717558501
1046,option,4.14367816091954
1047,quot interest,4.143416874957779
1048,dental insurance,4.142857142857142
1049,share trading,4.140986908358509
1050,ups,4.139717425431711
1051,fully exercise,4.136363636363637
1052,company,4.136033152187399
1053,risk,4.130733382389011
1054,market price,4.130204992456205
1055,comparable asset,4.128549303045947
1056,magic leap,4.126984126984127
1057,plan amendment,4.126881720430108
1058,accounting retrospectively,4.126436781609195
1059,york,4.124488124488124
1060,term improvement,4.124411704522202
1061,fiscal period,4.124101713653952
1062,subsequently marked,4.117647058823529
1063,subsequently amortize,4.117647058823529
1064,capital,4.117493472584856
1065,contributed capital,4.117493472584856
1066,working capital,4.117493472584856
1067,borrowed capital,4.117493472584856
1068,capital resources,4.117493472584856
1069,capital resource,4.117493472584856
1070,lease,4.116801437556155
1071,income,4.1155270034843205
1072,future payment,4.115474815359305
1073,additional indebtedness,4.112676056338028
1074,future growth,4.112359550561798
1075,foreseeable future,4.112359550561798
1076,fasb clarified,4.111111111111111
1077,fasb voted,4.111111111111111
1078,private security,4.110840750464238
1079,annual report,4.109523809523809
1080,capital,4.107969663061047
1081,performance condition,4.107731958762887
1082,historical investment,4.107131690401069
1083,actual result,4.106128550074738
1084,fund,4.1054150743962925
1085,loss,4.104713823813035
1086,consisting primarily,4.104627766599598
1087,employee headcount,4.103174603174603
1088,september primarily,4.097778451531104
1089,expense,4.093657649465788
1090,performance risk,4.092169044855602
1091,potential growth,4.091666666666667
1092,asset quot,4.091108867375423
1093,accelerator,4.088224012274646
1094,invested capital,4.087190442281826
1095,expense amortization,4.086919104991394
1096,ha entered,4.085769980506822
1097,tax cost,4.085707502374169
1098,raw material,4.085585585585585
1099,financial liability,4.082546930492136
1100,june,4.082186606227403
1101,management,4.08128254316251
1102,total portfolio,4.0793428425878755
1103,derivative held,4.078884462151395
1104,made quarterly,4.07563025210084
1105,resource,4.07563025210084
1106,remaining investor,4.073913043478261
1107,equity investment,4.072287635820173
1108,wa valued,4.070364932885906
1109,investment community,4.070094653364032
1110,award share,4.070064922542906
1111,semiconductor business,4.06989247311828
1112,business activity,4.06989247311828
1113,synthesis business,4.06989247311828
1114,molecular imprints,4.069767441860465
1115,option,4.066755083996464
1116,define impactful,4.065934065934066
1117,full potential,4.065
1118,liquid capital,4.064861893637488
1119,legal accounting,4.063936781609195
1120,plan prior,4.063918757467144
1121,financial result,4.0627495546409484
1122,relative seniority,4.0588235294117645
1123,equity round,4.054950776221128
1124,net settlement,4.054166666666667
1125,relevant input,4.054054054054054
1126,factor,4.053377814845705
1127,company,4.051377067531314
1128,administration expense,4.051204819277109
1129,ready market,4.050043516100957
1130,market movement,4.050043516100957
1131,company,4.049198418293842
1132,forfeiture,4.045542635658915
1133,ten year,4.044543034605146
1134,active market,4.044296389664176
1135,closed option,4.043678160919541
1136,oncology,4.043478260869565
1137,biovex group,4.043032786885246
1138,loss,4.042430086788814
1139,volatility,4.036759189797449
1140,fee payment,4.034171165418625
1141,utilization fee,4.0310559006211175
1142,fee,4.0310559006211175
1143,amount,4.030736314003247
1144,investment partners,4.02708390067586
1145,individual employed,4.027027027027027
1146,permit individual,4.027027027027027
1147,sionyx converted,4.026470588235294
1148,future price,4.025854360250379
1149,varying stage,4.022727272727273
1150,income,4.0217770034843205
1151,subsequent year,4.021768707482993
1152,subsequently closed,4.017647058823529
1153,readily marketable,4.017543859649123
1154,additional milestone,4.016021781245091
1155,investment,4.015645782182093
1156,specific fact,4.015151515151515
1157,owned historically,4.010909090909091
1158,business term,4.009118992455296
1159,investment income,4.008538323515019
1160,substantially relative,4.00427807486631
1161,interim period,4.003731343283582
1162,initial payment,4.003115264797508
1163,agreement,4.00289156626506
1164,internally managed,4.0
1165,united states,4.0
1166,parallel universes,4.0
1167,geo semiconductor,4.0
1168,broad category,4.0
1169,continued appropriateness,4.0
1170,expenses,4.0
1171,administrative agent,4.0
1172,kind dividend,4.0
1173,deduction,4.0
1174,credit,4.0
1175,north carolina,4.0
1176,balance sheet,4.0
1177,direct deduction,4.0
1178,inherently illiquid,4.0
1179,thing matures,4.0
1180,assign probability,4.0
1181,amendment limit,4.0
1182,fully expensed,4.0
1183,combination,4.0
1184,emerging field,4.0
1185,thing,4.0
1186,symbol enum,4.0
1187,symbol,4.0
1188,corden pharmaceuticals,4.0
1189,banker,4.0
1190,successfully executing,4.0
1191,resource constraint,4.0
1192,thomson reuters,4.0
1193,lifetime,4.0
1194,fractured syndicate,4.0
1195,global economy,4.0
1196,protection,4.0
1197,credit spread,4.0
1198,broader array,4.0
1199,ngx bio,4.0
1200,ohso clean,4.0
1201,conventional channel,4.0
1202,substantial doubt,4.0
1203,practical expedient,4.0
1204,pari passu,4.0
1205,manage pursuant,4.0
1206,deferred rent,4.0
1207,nano terra,4.0
1208,recent round,3.9994244604316544
1209,share,3.997810174577749
1210,financial assets,3.99616902716508
1211,amended including,3.9943181818181817
1212,subsequent period,3.9918265813788203
1213,payment,3.9914873578207635
1214,current period,3.9909108304630694
1215,profit interest,3.9885496183206106
1216,interest,3.9885496183206106
1217,interest,3.9885496183206106
1218,interest dividend,3.9885496183206106
1219,total primary,3.9846542346542346
1220,additional factor,3.9842356893655513
1221,good faith,3.980392156862745
1222,additional detail,3.9793427230046947
1223,payment,3.9785251008630818
1224,remaining life,3.977777777777778
1225,york,3.972972972972973
1226,single amount,3.9692431561996777
1227,legal fee,3.968555900621118
1228,high weighting,3.967741935483871
1229,trade publicly,3.966295609152752
1230,amount,3.966137566137566
1231,increased level,3.965729688101656
1232,future distribution,3.965300727032386
1233,aggregate intrinsic,3.963302752293578
1234,agtech,3.962962962962963
1235,period,3.9620646766169156
1236,indemnity escrow,3.9612745098039217
1237,private transaction,3.9604488078541378
1238,generally classify,3.9572235673930587
1239,undisclosed buyer,3.95640802092415
1240,include multiple,3.955754771544245
1241,remaining maturity,3.9555555555555557
1242,single present,3.9550962223806128
1243,investment commitment,3.95444839486063
1244,primarily owing,3.9542990158524365
1245,owing primarily,3.9542990158524365
1246,december notes,3.953183520599251
1247,wa amortized,3.9520613614573348
1248,future valuation,3.951534808293756
1249,comparable company,3.947388463542711
1250,security,3.9462444771723124
1251,comparable period,3.9460390355912747
1252,additional certification,3.946009389671361
1253,operations,3.945557579437361
1254,approximately half,3.945482866043614
1255,substantially reduced,3.9454545454545453
1256,substantially equivalent,3.9454545454545453
1257,deemed worthless,3.9444444444444446
1258,summary,3.9424317277343217
1259,accounting standard,3.9412515964240105
1260,depository account,3.9387755102040813
1261,credit arrangement,3.9375
1262,gas industry,3.9375
1263,existing investment,3.9367613200306986
1264,accelerator,3.9367088607594938
1265,accelerator,3.9367088607594938
1266,investments,3.935807560137457
1267,significant subsidiary,3.932544114362296
1268,asu doe,3.9313186813186816
1269,portfolio company,3.93057745997674
1270,similar manner,3.9305555555555554
1271,necessarily indicative,3.9302325581395348
1272,business plan,3.93010752688172
1273,integral part,3.9298245614035086
1274,salary benefit,3.9298245614035086
1275,potential return,3.9291666666666667
1276,expected term,3.9275986123602724
1277,agtech agtech,3.925925925925926
1278,road show,3.9259259259259256
1279,equity security,3.924627935818929
1280,prior round,3.9231281641353584
1281,impactful event,3.9230769230769234
1282,unconsolidated entity,3.9230769230769234
1283,treasury security,3.9224349533627887
1284,company,3.9217474379016846
1285,period,3.9203980099502487
1286,exit multiple,3.9194577352472093
1287,partially offset,3.916666666666667
1288,revenue recognition,3.915
1289,strike price,3.913494809688581
1290,investment pace,3.9132319082659923
1291,full term,3.9125598526703502
1292,investment portfolio,3.91225800877242
1293,portfolio investment,3.91225800877242
1294,sec,3.9117647058823533
1295,sec,3.9117647058823533
1296,current investor,3.911092530657748
1297,cash,3.909871244635193
1298,cash monthly,3.909871244635193
1299,cash resource,3.909871244635193
1300,capital structure,3.909160139251523
1301,security,3.9069310773937964
1302,milestone payment,3.906460989704571
1303,product development,3.90625
1304,additional paid,3.9051288865267075
1305,milestone,3.903345724907063
1306,payment,3.9031152647975076
1307,portfolio day,3.902769416014449
1308,independent director,3.902052785923754
1309,greater volatility,3.901328273244782
1310,annually distribute,3.9
1311,hierarchy indicating,3.9
1312,significant development,3.8987603305785123
1313,premium,3.898486759142497
1314,company doe,3.897937914092161
1315,approximately year,3.8958230020980356
1316,capital,3.8957361504091237
1317,investment quot,3.8916285766678667
1318,energy investments,3.890807560137457
1319,invested historically,3.8896969696969697
1320,main driver,3.888888888888889
1321,real driver,3.888888888888889
1322,deal team,3.888888888888889
1323,microcapitalization company,3.8884141045683513
1324,ordinary income,3.887161618868936
1325,wave systems,3.8859529025191675
1326,cash,3.885281080700767
1327,public financing,3.8845208845208843
1328,cash holding,3.8812998160637644
1329,company,3.8800807712350185
1330,address problem,3.878787878787879
1331,management resource,3.8764044943820224
1332,expectation,3.876190476190476
1333,remaining share,3.8743202416918425
1334,accelerator accelerator,3.8734177215189876
1335,amendment,3.872300469483568
1336,subjective factor,3.8715596330275233
1337,valuation procedures,3.8704252577319584
1338,transaction,3.8672811059907835
1339,effectively settled,3.8666666666666667
1340,future period,3.8660908938453797
1341,future amount,3.864211402413649
1342,guidance,3.8630831643002024
1343,security,3.861828892756728
1344,discussed previously,3.8606060606060604
1345,payment,3.860258121940365
1346,participant,3.860215053763441
1347,withholding share,3.858935626307227
1348,underlying principle,3.857142857142857
1349,healthcare cost,3.8549382716049383
1350,revenue standard,3.854814814814815
1351,significant estimate,3.8538885357067176
1352,multiple round,3.851003407800076
1353,material part,3.848743480322428
1354,estimated time,3.847963800904977
1355,differ significantly,3.8438133874239346
1356,profit,3.84375
1357,ultimately realized,3.8433294886582083
1358,milestone discount,3.8427396643010026
1359,december,3.8420724094881393
1360,service period,3.841450641529196
1361,march primarily,3.84141066873683
1362,total asset,3.8400877645844087
1363,implied valuation,3.8391752577319584
1364,valuation,3.8391752577319584
1365,increasing valuation,3.8391752577319584
1366,ultimate return,3.8375
1367,return variations,3.8375
1368,front payment,3.8364485981308407
1369,exit volatility,3.836265884652981
1370,credit risk,3.8344370860927155
1371,risk,3.8344370860927155
1372,risk adverse,3.8344370860927155
1373,america gaap,3.8333333333333335
1374,prescribed guideline,3.833333333333333
1375,guideline,3.833333333333333
1376,information,3.832482993197279
1377,additional round,3.8321005167696827
1378,future round,3.8317840109934522
1379,accounting estimate,3.8315649867374004
1380,company,3.8307110233358586
1381,net impact,3.829605263157895
1382,deep dilution,3.8295454545454546
1383,asu revenue,3.8284615384615384
1384,fund,3.826530612244898
1385,note fair,3.8255819108845044
1386,individual level,3.822945394373966
1387,liquidation,3.82258064516129
1388,aggregate cost,3.8182410238985165
1389,licensing,3.8181818181818183
1390,ten time,3.8147157190635452
1391,affect vesting,3.813967136150235
1392,investment,3.812391572131539
1393,difficult market,3.8119482780057194
1394,wa achieved,3.8092042186001915
1395,company,3.802699818854066
1396,notice,3.8
1397,quarterly report,3.8
1398,official notice,3.8
1399,share,3.7993202416918432
1400,chart show,3.7954911433172303
1401,assumption words,3.7954545454545454
1402,dividend,3.7924528301886795
1403,rent,3.7924528301886795
1404,restricted share,3.792149699056184
1405,return,3.7920454545454545
1406,occurred leaving,3.791666666666667
1407,asu revise,3.7884615384615383
1408,exit event,3.787878787878788
1409,additional investor,3.7865890998162888
1410,receive approximately,3.7837913237550564
1411,attained year,3.783673469387755
1412,year deferral,3.783673469387755
1413,taxable year,3.783673469387755
1414,portfolio securities,3.782639545884579
1415,change,3.7821366237772454
1416,fee,3.781055900621118
1417,forfeited owing,3.7782426778242675
1418,equity ownership,3.776204281891169
1419,senior preference,3.770516717325228
1420,insurance contract,3.767857142857143
1421,portfolio security,3.764598308771177
1422,individual investment,3.7637883470577256
1423,high level,3.76366030283081
1424,quantitative information,3.7630385487528346
1425,net assets,3.7603813559322035
1426,significant effect,3.758516428139488
1427,time,3.757549857549858
1428,primary methodology,3.757278669043375
1429,full year,3.7570068027210883
1430,repurchase program,3.756043956043956
1431,offs,3.7551020408163263
1432,partial write,3.7551020408163263
1433,downs,3.7551020408163263
1434,delaware company,3.7550807712350185
1435,company,3.7550807712350185
1436,company consolidates,3.7550807712350185
1437,company,3.7550807712350185
1438,company,3.7550807712350185
1439,company,3.7550807712350185
1440,company,3.7550807712350185
1441,weak company,3.7550807712350185
1442,company variations,3.7550807712350185
1443,company,3.7550807712350185
1444,company,3.7550807712350185
1445,company,3.7550807712350185
1446,ourportfolio company,3.7550807712350185
1447,company matures,3.7550807712350185
1448,quot accumulated,3.7548672566371684
1449,considered issued,3.7542087542087543
1450,share,3.7532047038432372
1451,share,3.7532047038432372
1452,amount,3.7518518518518515
1453,substantial amount,3.7518518518518515
1454,valued based,3.751753048780488
1455,leadership position,3.75
1456,outstanding borrowing,3.75
1457,position,3.75
1458,considerable pressure,3.75
1459,continued pressure,3.75
1460,september,3.7493083203994875
1461,purchased share,3.7470475144191155
1462,sec certification,3.7450980392156863
1463,volatility,3.744039270687237
1464,statements,3.7433155080213907
1465,related amount,3.742328042328042
1466,stage round,3.7421517331589276
1467,outstanding principal,3.7403846153846154
1468,present,3.7377049180327866
1469,initial investment,3.7367613200306984
1470,investment transactions,3.7367613200306984
1471,investment,3.7367613200306984
1472,investment yields,3.7367613200306984
1473,investment adviser,3.7367613200306984
1474,investment manager,3.7367613200306984
1475,guidance,3.735632183908046
1476,proceeds,3.734445980643887
1477,proceeds,3.734445980643887
1478,insured limit,3.7333333333333334
1479,portfolio maturity,3.7310522442972776
1480,entity,3.730769230769231
1481,company,3.730490607300592
1482,quarter payments,3.7286713286713287
1483,actively involved,3.7272727272727275
1484,involved actively,3.7272727272727275
1485,chronic disease,3.7272727272727275
1486,undiagnosed disease,3.7272727272727275
1487,date,3.726851851851852
1488,full amount,3.725185185185185
1489,applies fair,3.7248868778280544
1490,company,3.724777740931988
1491,prepayment,3.7241379310344827
1492,portfolio summary,3.7231157363607696
1493,definitive agreement,3.7228915662650603
1494,agreement,3.7228915662650603
1495,asset amortization,3.721955896452541
1496,amount,3.7215488215488213
1497,greater detail,3.719607843137255
1498,closing fee,3.7195804907850523
1499,round additionally,3.7194244604316546
1500,managing member,3.716666666666667
1501,outstanding security,3.7141016200294548
1502,operating result,3.7137981665939126
1503,previously generally,3.709604519774011
1504,lowest level,3.705009276437848
1505,dollar,3.704878048780488
1506,financing event,3.7027027027027026
1507,financing activity,3.7027027027027026
1508,company,3.70244919228765
1509,exit price,3.701373597567369
1510,coming year,3.7003401360544217
1511,september,3.6999647913272034
1512,act overview,3.699248120300752
1513,amount,3.6992202729044834
1514,fiscal quarter,3.699041699041699
1515,termination fee,3.6977225672877845
1516,entity,3.6974132062627643
1517,level hierarchy,3.6959183673469385
1518,warrant wa,3.6959037259893543
1519,related estimate,3.695604395604396
1520,company,3.6938562814391
1521,net increase,3.6936889250814335
1522,company accelerator,3.691789631994512
1523,financing,3.6910747957259584
1524,series,3.6906710310965627
1525,return greater,3.6904411764705882
1526,note,3.6889303271740976
1527,greater risk,3.6873782625633034
1528,operation expense,3.687031590930652
1529,opgen,3.684584980237154
1530,june,3.6843729460235015
1531,lower fair,3.680769230769231
1532,security,3.6800107109385456
1533,sm ventures,3.67741935483871
1534,lease term,3.6750755759407903
1535,accredited investor,3.6739130434782608
1536,interested investor,3.6739130434782608
1537,initial investor,3.6739130434782608
1538,investment asset,3.6730029307689533
1539,valuation guideline,3.672508591065292
1540,early repayment,3.6719858156028367
1541,september administration,3.6717221135029354
1542,awarrant,3.671641791044776
1543,principally comprised,3.66875
1544,future success,3.667915106117353
1545,future source,3.667915106117353
1546,approximately million,3.667705088265836
1547,presidential election,3.666666666666667
1548,liability,3.6641373080397472
1549,opgen,3.6626203676685147
1550,valuation technique,3.66060382916053
1551,lease,3.6589259796806965
1552,accomplishment,3.6575091575091574
1553,investment,3.6567613200306983
1554,june administration,3.6561302681992336
1555,total amount,3.6556980056980057
1556,interest accrue,3.6552162849872776
1557,quot warrants,3.6548672566371683
1558,escrow,3.651811594202899
1559,differ substantially,3.651336898395722
1560,fund,3.6507064364207222
1561,consulting agreement,3.6459684893419837
1562,previously reported,3.6449612403100775
1563,initial preference,3.642857142857143
1564,preference,3.642857142857143
1565,level inputs,3.642072213500785
1566,expense,3.6412048192771085
1567,diluted share,3.640986908358509
1568,registration statement,3.638364779874214
1569,primary source,3.6363636363636367
1570,secured creditor,3.6358974358974354
1571,liquidity,3.6341459143287453
1572,round price,3.6329192701202357
1573,regular review,3.6315789473684212
1574,future date,3.630878069080316
1575,company,3.6300807712350185
1576,consistent definition,3.625
1577,ipo market,3.616710182767624
1578,general restriction,3.6166121112929623
1579,portfolio ownership,3.616174654843417
1580,ordinary dividend,3.6153846153846154
1581,future circumstance,3.6123595505617976
1582,company,3.6122236283778753
1583,risk uncertainty,3.612214863870493
1584,payment,3.611448598130841
1585,exercise share,3.610683878055479
1586,ipo strategy,3.6083333333333334
1587,adversely affect,3.6056338028169015
1588,affect negatively,3.6056338028169015
1589,net sale,3.6050000000000004
1590,measurement,3.604878048780488
1591,december method,3.6042738632783786
1592,warrant including,3.60423197492163
1593,identical asset,3.6029082774049215
1594,asset denotes,3.6029082774049215
1595,financing closed,3.6027027027027025
1596,closing price,3.602019399852516
1597,uncertainty,3.6019536019536016
1598,share outstanding,3.599320241691843
1599,difficult complex,3.5952380952380953
1600,quot transaction,3.5935769340565233
1601,single point,3.592391304347826
1602,portfolio investments,3.5913042488791787
1603,significant impact,3.590865593736407
1604,execution,3.5904761904761906
1605,security taking,3.5891016200294548
1606,updated analysis,3.588888888888889
1607,additional share,3.586996298029871
1608,net decrease,3.586886503067485
1609,quot fair,3.585636487406399
1610,directors,3.5851795263559967
1611,quot footnote,3.5834386852085967
1612,speculative nature,3.583333333333333
1613,exit assumption,3.583333333333333
1614,specialized nature,3.583333333333333
1615,interdisciplinary nature,3.583333333333333
1616,company,3.58266697813157
1617,impact,3.5800362976406532
1618,amount,3.5794380587484036
1619,company,3.5792565954108424
1620,capital,3.579031934123318
1621,investment return,3.5742613200306983
1622,provide medical,3.5728155339805827
1623,remaining warrant,3.572413793103448
1624,investments quot,3.570674816774625
1625,business prospect,3.5698924731182795
1626,fair statement,3.5691340106434444
1627,table,3.568965517241379
1628,table,3.568965517241379
1629,explicit guidance,3.568965517241379
1630,guidance lessee,3.568965517241379
1631,valuation,3.566447985004686
1632,ha elected,3.5655270655270654
1633,share,3.565229332600934
1634,favorable term,3.5642265193370166
1635,accounting record,3.5639367816091956
1636,fund investment,3.5632919322755963
1637,security holding,3.5605301914580263
1638,money option,3.5603448275862073
1639,nanoscale patterning,3.5555555555555554
1640,champions maturity,3.5555555555555554
1641,qualitative input,3.554054054054054
1642,time,3.5538461538461537
1643,time,3.5538461538461537
1644,time,3.5538461538461537
1645,ventures management,3.5538238492207324
1646,approximately percent,3.553676979010996
1647,company,3.5475336014236976
1648,period,3.545398009950249
1649,higher price,3.5450737570570023
1650,company,3.5445544554455446
1651,amount,3.544304682040531
1652,estimated enterprise,3.5441176470588234
1653,management belief,3.5430711610486894
1654,expected time,3.5422182468694094
1655,recognize revenue,3.54
1656,valuation,3.5391752577319586
1657,year period,3.5374048126713373
1658,potential impact,3.5337719298245616
1659,level investment,3.5326796873776374
1660,percent,3.532436537209807
1661,annual letter,3.5317460317460316
1662,material effect,3.5286750164798946
1663,individual responsible,3.527027027027027
1664,invested million,3.525252525252525
1665,investee company,3.5225226317001344
1666,share exclusive,3.5219392893108905
1667,sold substantially,3.5199226305609286
1668,digital technology,3.519230769230769
1669,biochemical technology,3.519230769230769
1670,dividend date,3.5185185185185186
1671,share,3.516873433181204
1672,valuation methodology,3.515645845967253
1673,general assignment,3.512765957446809
1674,investor risk,3.5083501295709763
1675,certification,3.5049751243781095
1676,period,3.503731343283582
1677,landlord payment,3.5031152647975077
1678,canadian dollar,3.5
1679,computer equipment,3.5
1680,profitability,3.5
1681,began realizing,3.5
1682,began building,3.5
1683,financially support,3.5
1684,pension obligation,3.5
1685,potential shareholder,3.4990740740740742
1686,contingent asset,3.498741610738255
1687,transfer,3.4974137931034486
1688,investment company,3.491842091265717
1689,interest,3.4885496183206106
1690,additional repurchase,3.4841046277665995
1691,future repurchase,3.483788121990369
1692,transaction,3.4812628689087166
1693,day period,3.4810040705563097
1694,meet quarterly,3.4761904761904763
1695,annual assessment,3.4761904761904763
1696,share,3.474320241691843
1697,share vest,3.474320241691843
1698,share borrowings,3.474320241691843
1699,share,3.474320241691843
1700,share,3.474320241691843
1701,escrowed share,3.474320241691843
1702,unissued share,3.474320241691843
1703,liquidation preference,3.4654377880184333
1704,ultimately realize,3.465079365079365
1705,contingencies,3.462559564329476
1706,security,3.4614420455613697
1707,primary focus,3.460118425635667
1708,accounting applied,3.459770114942529
1709,bridgelux,3.4592105263157893
1710,significant increase,3.4549492556599457
1711,rate,3.454844634930353
1712,participation agreement,3.450164293537788
1713,interim decrease,3.4493865030674846
1714,director fee,3.4492377188029364
1715,business focus,3.449202817945866
1716,part,3.4483430799220276
1717,disclosure,3.4482758620689653
1718,unrestricted security,3.4462444771723124
1719,dividend,3.4444444444444446
1720,march,3.443597008532929
1721,future quarter,3.4410308792331263
1722,trade significantly,3.4409613375130617
1723,substantial ownership,3.4406779661016946
1724,increasing ownership,3.4406779661016946
1725,options quot,3.4405815423514543
1726,detail,3.439482200647249
1727,finally result,3.4394618834080717
1728,company,3.439291297550808
1729,orderly transaction,3.4387096774193546
1730,company ventures,3.432500126073728
1731,measuring fair,3.430769230769231
1732,approximates fair,3.430769230769231
1733,proceeds,3.4306779356230894
1734,percent interest,3.4300770646213268
1735,entity,3.4230769230769234
1736,security,3.4224349533627882
1737,company,3.421747437901685
1738,diverse set,3.4210526315789473
1739,applicable regulation,3.418158567774936
1740,coming decade,3.416666666666667
1741,activity,3.416666666666667
1742,price,3.413494809688581
1743,section,3.412280701754386
1744,return,3.410315533980582
1745,shareholder,3.4074074074074074
1746,methodology,3.4037433155080214
1747,directors,3.403361344537815
1748,ipo,3.4
1749,measurement,3.4
1750,quot,3.397291499061411
1751,investor agreement,3.396804609743321
1752,biology company,3.395080771235018
1753,directors interest,3.3919109628584256
1754,license agreement,3.3895582329317273
1755,amount,3.3882154882154882
1756,reconcile change,3.387323943661972
1757,operation,3.3858267716535435
1758,operations quot,3.38437545335848
1759,ha shut,3.3832528180354267
1760,adjustment,3.380184331797235
1761,initial focus,3.3793103448275863
1762,period,3.378731343283582
1763,potential pipeline,3.3773809523809524
1764,management support,3.3764044943820224
1765,reduced access,3.375
1766,party,3.366883116883117
1767,larger percentage,3.3636363636363633
1768,escrow period,3.3620646766169155
1769,material impact,3.3610241820768136
1770,valuation date,3.3576937762504775
1771,company,3.355080771235018
1772,level input,3.3499724214009925
1773,financing,3.3497615262321143
1774,registered share,3.349320241691843
1775,significant decrease,3.348146833645997
1776,voting share,3.346660667223758
1777,january enum,3.3461538461538463
1778,government security,3.3451991810050647
1779,legal restriction,3.3413461538461537
1780,vest,3.34
1781,july bridgelux,3.339516129032258
1782,valuation,3.3391752577319584
1783,critical valuation,3.3391752577319584
1784,security,3.3391016200294548
1785,transaction,3.338709677419355
1786,monetize asset,3.336241610738255
1787,applied retrospectively,3.333333333333333
1788,otisville biotech,3.333333333333333
1789,subjective judgment,3.333333333333333
1790,unrestricted share,3.3314630988347
1791,amount,3.3307992202729046
1792,hierarchy fair,3.3307692307692305
1793,full abatement,3.3304761904761904
1794,future sale,3.329859550561798
1795,invest primarily,3.3291175625179648
1796,calendar quarter,3.3286713286713288
1797,effective yield,3.326020184291356
1798,conversion event,3.3243243243243246
1799,adjustment factor,3.3231725362533293
1800,responsible party,3.321428571428571
1801,proceeds,3.3145917001338687
1802,ability,3.313725490196078
1803,synglyco beginning,3.312781954887218
1804,timing constraint,3.3076923076923075
1805,table,3.306670435274166
1806,asset class,3.3066119811086256
1807,company,3.3005353166895635
1808,commission,3.3
1809,competitive advantage,3.3
1810,specific number,3.299465240641711
1811,limited owing,3.2967611963427865
1812,limited partnership,3.2962962962962963
1813,greater ownership,3.2936191425722834
1814,investment maturity,3.2923168755862537
1815,january substantially,3.291608391608392
1816,valuation adjustment,3.2907881609577654
1817,fund,3.288069073783359
1818,achieved irrespective,3.2857142857142856
1819,achieved successfully,3.2857142857142856
1820,fully exercisable,3.2857142857142856
1821,investment,3.2836363200306984
1822,amortized cost,3.283509700176367
1823,unregistered security,3.2766016200294548
1824,quantitative input,3.2762762762762763
1825,technology company,3.2743115404657877
1826,security,3.273312146345244
1827,fair valuation,3.2699444885011895
1828,sec regulation,3.264705882352941
1829,conversion term,3.263550843661341
1830,amount,3.2634797588285958
1831,amount,3.2634797588285958
1832,borrowing equal,3.2613636363636367
1833,increase,3.2607343796268875
1834,company default,3.2550807712350185
1835,building company,3.2550807712350185
1836,share inclusive,3.2520980194696207
1837,amount,3.2518518518518515
1838,successful completion,3.25
1839,section,3.245614035087719
1840,voting class,3.242710795902285
1841,required date,3.2426564495530013
1842,small difference,3.240027045300879
1843,partial drawdown,3.238095238095238
1844,directors,3.2366946778711485
1845,pronounced issue,3.2222222222222223
1846,acquisition quot,3.221533923303835
1847,operations,3.219984387197502
1848,significant portion,3.21918286578978
1849,partial sale,3.2175000000000002
1850,fund operation,3.212357383898441
1851,liability,3.2092592592592593
1852,smaller board,3.203488372093023
1853,length financing,3.2027027027027026
1854,lease liability,3.195108315863033
1855,investments,3.194050237961725
1856,july synglyco,3.1930875576036866
1857,limited investor,3.19243156199678
1858,indirectly borne,3.1875
1859,company,3.1868989530532
1860,opgen,3.1867494824016562
1861,settlement date,3.185185185185185
1862,earnings loss,3.183606557377049
1863,defined price,3.1827255789193503
1864,ipo,3.1777777777777776
1865,full board,3.176821705426357
1866,investment transaction,3.175470997450053
1867,company investments,3.1708883313724754
1868,level assets,3.1687997232791423
1869,investment,3.16857950184888
1870,participate accelerator,3.1674780915287246
1871,simplified calculation,3.166666666666667
1872,invest opportunistically,3.1530612244897958
1873,invest alongside,3.1530612244897958
1874,investment investments,3.1525688801681557
1875,effective date,3.1464254952627044
1876,consideration,3.142452830188679
1877,determining fair,3.1307692307692307
1878,yield fair,3.128882438316401
1879,reason,3.127272727272727
1880,pension liability,3.1259259259259258
1881,sale milestone,3.1208457249070634
1882,august uberseq,3.12063492063492
1883,investment series,3.1197400434349536
1884,disposition date,3.1185185185185187
1885,normal number,3.1176470588235294
1886,highly volatile,3.1153846153846154
1887,interome,3.114285714285714
1888,day operation,3.1130994989262706
1889,offering ipos,3.111111111111111
1890,differ materially,3.105882352941176
1891,transaction,3.1053763440860216
1892,considered include,3.096903096903097
1893,company,3.0950807712350183
1894,warrant,3.089080459770115
1895,company,3.0884141045683515
1896,company,3.0884141045683515
1897,past year,3.0836734693877554
1898,periodic follow,3.074626865671642
1899,maturity date,3.0740740740740744
1900,largest investment,3.0700946533640314
1901,control valuation,3.0613974799541808
1902,judgment,3.057471264367816
1903,concern uncertainty,3.0555555555555554
1904,share,3.048788326798226
1905,nvca,3.0440251572327046
1906,maturing company,3.040795056949304
1907,security adjustment,3.0407145232552617
1908,opportunity,3.0384615384615383
1909,consolidation analysis,3.0359477124183005
1910,interest,3.034004163775156
1911,management,3.0326544943820224
1912,closed end,3.028205128205128
1913,company,3.0243115404657877
1914,investment history,3.022475605744984
1915,august sionyx,3.019327731092437
1916,principal measure,3.0153846153846153
1917,materially affect,3.0056338028169014
1918,warrant,3.0
1919,fourth quarter,2.9953379953379953
1920,transaction,2.9942652329749104
1921,ended,2.9913978494623654
1922,table,2.990018148820327
1923,operation,2.985826771653543
1924,shareholder,2.98022294138799
1925,fair valued,2.977644230769231
1926,decrease,2.9776291808917525
1927,effective january,2.974060822898032
1928,directors,2.965861344537815
1929,shareholder approval,2.962962962962963
1930,ipo maturity,2.9555555555555557
1931,fair presentation,2.9545787545787547
1932,range level,2.9497645211930923
1933,access,2.9478155339805827
1934,estimate,2.9475524475524475
1935,transaction,2.9387096774193546
1936,share,2.9187646861362873
1937,equipment property,2.9047619047619047
1938,measurement warrants,2.9
1939,generally increase,2.882460111522111
1940,assistance,2.88
1941,board belief,2.87015503875969
1942,lease subject,2.8670990566037737
1943,warrant,2.844055584148224
1944,percent,2.8415274463007156
1945,development,2.8397435897435894
1946,nantero proceeds,2.839036144578313
1947,observable input,2.8318318318318316
1948,measure fair,2.8307692307692305
1949,present continue,2.8274485077763765
1950,test,2.8260869565217392
1951,march opgen,2.80448476549127
1952,ownership percentage,2.8043143297380584
1953,operations property,2.800936768149883
1954,exists,2.8
1955,acquisition agreement,2.7895582329317268
1956,purchase share,2.78417939662142
1957,share purchase,2.78417939662142
1958,situation,2.776271186440678
1959,providing,2.764705882352941
1960,time,2.7643724696356275
1961,share,2.756928937344017
1962,convertible,2.7547169811320753
1963,liability,2.753376906318083
1964,director seat,2.7515151515151515
1965,purchase percent,2.751386601230293
1966,totaling,2.75
1967,percent increase,2.747716371382149
1968,adoption,2.7333333333333334
1969,generally expect,2.7233300099700894
1970,date,2.697089947089947
1971,manner timing,2.6826923076923075
1972,recognize transfer,2.6724137931034484
1973,ownership,2.6714471968709255
1974,china,2.6666666666666665
1975,convert,2.6666666666666665
1976,transaction sale,2.656209677419355
1977,percent decrease,2.6409139493682003
1978,focused,2.6315789473684212
1979,financial,2.6232876712328768
1980,applied prospectively,2.619047619047619
1981,pricing,2.607142857142857
1982,line,2.6
1983,traded,2.5961538461538463
1984,award,2.595744680851064
1985,average,2.585714285714286
1986,currency,2.5833333333333335
1987,board representation,2.578488372093023
1988,month,2.577413479052823
1989,granted,2.5714285714285716
1990,requirement,2.5652173913043477
1991,acquired percent,2.559174505124245
1992,identify forward,2.5454545454545454
1993,firm,2.5416666666666665
1994,listed,2.5384615384615383
1995,board seat,2.536821705426356
1996,committee,2.5267857142857144
1997,bdc subject,2.5158653846153847
1998,decrease,2.5055754281489175
1999,scenario,2.5
2000,commonly invest,2.4863945578231292
2001,percent,2.4855526035334203
2002,transaction,2.4827348346520592
2003,issued,2.4814814814814814
2004,sector,2.4782608695652173
2005,warrant trade,2.475444096133751
2006,energy,2.475
2007,identified,2.473684210526316
2008,comprehensive,2.4545454545454546
2009,resulting,2.450980392156863
2010,lesser extent,2.4447674418604652
2011,secured,2.4358974358974357
2012,including,2.4318181818181817
2013,adesto,2.425
2014,medicine,2.423076923076923
2015,electronics,2.4193548387096775
2016,early,2.4166666666666665
2017,corporation,2.4069767441860463
2018,call,2.4
2019,expectation,2.4
2020,remaining,2.4
2021,note,2.394812680115274
2022,officer,2.3902439024390243
2023,net,2.3875
2024,program,2.3846153846153846
2025,complete,2.375
2026,converted,2.35
2027,basis,2.3376623376623376
2028,equity,2.335526315789474
2029,reliable,2.3333333333333335
2030,merger,2.3333333333333335
2031,vary,2.3333333333333335
2032,november opgen,2.332678821879383
2033,liquidity,2.327956989247312
2034,represent,2.325
2035,stock,2.322274881516588
2036,restricted,2.317829457364341
2037,method,2.317757009345794
2038,rate,2.316546762589928
2039,annual,2.3095238095238093
2040,expense,2.3012048192771086
2041,estimated,2.2941176470588234
2042,long,2.293103448275862
2043,preferred,2.283582089552239
2044,held,2.2788844621513946
2045,operating,2.274336283185841
2046,statements,2.272727272727273
2047,income,2.2717770034843205
2048,amendment,2.2666666666666666
2049,requires,2.264705882352941
2050,benefit,2.263157894736842
2051,exchange,2.257142857142857
2052,model,2.253012048192771
2053,holder,2.25
2054,offer,2.25
2055,categorized,2.25
2056,lower,2.25
2057,pattern,2.25
2058,current,2.2371794871794872
2059,accrued,2.2333333333333334
2060,april canon,2.2179144385026737
2061,commitment,2.2176870748299318
2062,market,2.216710182767624
2063,pay,2.212121212121212
2064,strategy,2.2083333333333335
2065,diversification,2.206896551724138
2066,based,2.204878048780488
2067,unobservable,2.2
2068,realization,2.2
2069,gain,2.1914893617021276
2070,improvement,2.185185185185185
2071,public,2.1818181818181817
2072,claim,2.176470588235294
2073,pace,2.176470588235294
2074,primarily,2.176056338028169
2075,portfolio,2.1754966887417218
2076,state,2.1724137931034484
2077,consolidated,2.1710144927536232
2078,increased,2.169811320754717
2079,adjusted,2.1666666666666665
2080,target,2.1666666666666665
2081,diluted,2.1666666666666665
2082,product,2.15625
2083,quot,2.1548672566371683
2084,approach,2.1507936507936507
2085,common,2.15
2086,significant,2.1487603305785123
2087,option,2.1436781609195403
2088,define,2.142857142857143
2089,doe,2.142857142857143
2090,statement,2.138364779874214
2091,significantly,2.1379310344827585
2092,exercise,2.1363636363636362
2093,loan,2.135135135135135
2094,health,2.135135135135135
2095,data,2.1333333333333333
2096,multiple,2.1315789473684212
2097,senior,2.127659574468085
2098,accounting,2.1264367816091956
2099,outstanding,2.125
2100,enabled,2.125
2101,group,2.125
2102,leaving,2.125
2103,realized,2.121107266435986
2104,capital,2.117493472584856
2105,additional,2.112676056338028
2106,future,2.1123595505617976
2107,approximately,2.1121495327102804
2108,anticipate,2.111111111111111
2109,fasb,2.111111111111111
2110,employee,2.1031746031746033
2111,consortium,2.1
2112,potential,2.091666666666667
2113,owned,2.090909090909091
2114,service,2.087719298245614
2115,primary,2.080808080808081
2116,made,2.0756302521008405
2117,business,2.0698924731182795
2118,applicable,2.0652173913043477
2119,depreciation,2.0607734806629834
2120,member,2.05
2121,volatility,2.0483870967741935
2122,exclusive,2.0476190476190474
2123,relating,2.0434782608695654
2124,decreased,2.0425531914893615
2125,information,2.0408163265306123
2126,revenue,2.04
2127,procedures,2.03125
2128,fee,2.031055900621118
2129,individual,2.027027027027027
2130,stage,2.022727272727273
2131,payment,2.0031152647975077
2132,mersana,2.0
2133,probability,2.0
2134,patent,2.0
2135,lender,2.0
2136,deferred,2.0
2137,additionally,2.0
2138,rent,2.0
2139,typically,2.0
2140,normal,2.0
2141,dividend,2.0
2142,pursuant,2.0
2143,treatment,2.0
2144,basic,2.0
2145,event,2.0
2146,credit,2.0
2147,reasonable,2.0
2148,law,2.0
2149,innovation,2.0
2150,back,2.0
2151,experience,2.0
2152,create,2.0
2153,offering,2.0
2154,champions,2.0
2155,discus,2.0
2156,growth,2.0
2157,substantial,2.0
2158,initial,2.0
2159,deal,2.0
2160,raise,2.0
2161,calculates,2.0
2162,redemption,2.0
2163,companies,2.0
2164,negotiated,2.0
2165,signed,2.0
2166,taxable,2.0
2167,continued,2.0
2168,related,1.9904761904761905
2169,interest,1.9885496183206106
2170,expected,1.9883720930232558
2171,loss,1.9836065573770492
2172,good,1.9803921568627452
2173,received,1.9754098360655739
2174,full,1.9733333333333334
2175,york,1.972972972972973
2176,holding,1.9714285714285715
2177,invested,1.9696969696969697
2178,small,1.9655172413793103
2179,aggregate,1.963302752293578
2180,agtech,1.962962962962963
2181,unaffiliated,1.9615384615384615
2182,generate,1.9545454545454546
2183,mature,1.9473684210526316
2184,includes,1.9473684210526316
2185,substantially,1.9454545454545455
2186,discount,1.9393939393939394
2187,term,1.9392265193370166
2188,account,1.9387755102040816
2189,industry,1.9375
2190,arrangement,1.9375
2191,accelerator,1.9367088607594938
2192,asset,1.936241610738255
2193,necessarily,1.930232558139535
2194,part,1.9298245614035088
2195,consisting,1.9285714285714286
2196,show,1.9259259259259258
2197,premium,1.9230769230769231
2198,impactful,1.9230769230769231
2199,september,1.9217221135029354
2200,historically,1.92
2201,material,1.9189189189189189
2202,biovex,1.9180327868852458
2203,offset,1.9166666666666667
2204,mid,1.9166666666666667
2205,coming,1.9166666666666667
2206,price,1.9134948096885813
2207,sec,1.911764705882353
2208,cash,1.909871244635193
2209,choose,1.9090909090909092
2210,june,1.9061302681992338
2211,total,1.9038461538461537
2212,milestone,1.903345724907063
2213,closed,1.9
2214,hierarchy,1.9
2215,collect,1.9
2216,buyer,1.8918918918918919
2217,writes,1.8888888888888888
2218,fees,1.8888888888888888
2219,team,1.8888888888888888
2220,address,1.878787878787879
2221,management,1.8764044943820224
2222,registered,1.875
2223,build,1.875
2224,voting,1.872340425531915
2225,factor,1.871559633027523
2226,chart,1.8695652173913044
2227,detail,1.8666666666666667
2228,settled,1.8666666666666667
2229,plan,1.8602150537634408
2230,due,1.8571428571428572
2231,unrestricted,1.8571428571428572
2232,influence,1.8571428571428572
2233,cost,1.8549382716049383
2234,distribution,1.8529411764705883
2235,greater,1.8529411764705883
2236,condition,1.85
2237,inputs,1.8461538461538463
2238,generated,1.84375
2239,valuation,1.8391752577319587
2240,return,1.8375
2241,risk,1.8344370860927153
2242,regulatory,1.8333333333333333
2243,certification,1.8333333333333333
2244,fact,1.8333333333333333
2245,obligation,1.8333333333333333
2246,guideline,1.8333333333333333
2247,active,1.8275862068965518
2248,represents,1.8275862068965518
2249,fund,1.8265306122448979
2250,include,1.8241758241758241
2251,liquidation,1.8225806451612903
2252,technique,1.8214285714285714
2253,party,1.8214285714285714
2254,selling,1.8181818181818181
2255,standard,1.8148148148148149
2256,report,1.8
2257,derivative,1.8
2258,declared,1.8
2259,demand,1.8
2260,level,1.7959183673469388
2261,assumption,1.7954545454545454
2262,paid,1.7924528301886793
2263,presented,1.7916666666666667
2264,structure,1.7916666666666667
2265,entered,1.7894736842105263
2266,asu,1.7884615384615385
2267,exit,1.7878787878787878
2268,amortization,1.7857142857142858
2269,subsidiary,1.7837837837837838
2270,year,1.7836734693877552
2271,owing,1.7782426778242677
2272,partner,1.7777777777777777
2273,uncertainty,1.7777777777777777
2274,uberseq,1.7777777777777777
2275,inclusive,1.7777777777777777
2276,partnership,1.7777777777777777
2277,bridgelux,1.775
2278,order,1.7692307692307692
2279,investee,1.7674418604651163
2280,proceeds,1.7590361445783131
2281,government,1.7560975609756098
2282,write,1.7551020408163265
2283,company,1.7550807712350183
2284,period,1.7537313432835822
2285,amount,1.7518518518518518
2286,denominated,1.75
2287,development,1.75
2288,position,1.75
2289,existed,1.75
2290,application,1.75
2291,draw,1.75
2292,administration,1.75
2293,rank,1.75
2294,pressure,1.75
2295,realize,1.7428571428571429
2296,present,1.7377049180327868
2297,investment,1.7367613200306984
2298,lease,1.7358490566037736
2299,limit,1.7333333333333334
2300,discussed,1.7272727272727273
2301,day,1.7272727272727273
2302,involved,1.7272727272727273
2303,disease,1.7272727272727273
2304,participation,1.7272727272727273
2305,required,1.7241379310344827
2306,agreement,1.7228915662650603
2307,ultimately,1.7222222222222223
2308,quantitative,1.7222222222222223
2309,round,1.7194244604316546
2310,executed,1.7142857142857142
2311,differ,1.7058823529411764
2312,met,1.7058823529411764
2313,estimate,1.705128205128205
2314,financing,1.7027027027027026
2315,determining,1.7
2316,act,1.699248120300752
2317,yield,1.6981132075471699
2318,derived,1.6956521739130435
2319,wave,1.6931818181818181
2320,closing,1.6885245901639345
2321,lead,1.6875
2322,unregistered,1.6875
2323,lack,1.6857142857142857
2324,readily,1.6842105263157894
2325,beginning,1.6842105263157894
2326,ventures,1.6774193548387097
2327,methodology,1.6764705882352942
2328,sionyx,1.6764705882352942
2329,investor,1.673913043478261
2330,receive,1.671641791044776
2331,identical,1.6666666666666667
2332,settlement,1.6666666666666667
2333,accrue,1.6666666666666667
2334,belief,1.6666666666666667
2335,decides,1.6666666666666667
2336,salary,1.6666666666666667
2337,pension,1.6666666666666667
2338,termination,1.6666666666666667
2339,fourth,1.6666666666666667
2340,occurred,1.6666666666666667
2341,license,1.6666666666666667
2342,march,1.6653543307086613
2343,occur,1.6470588235294117
2344,consolidation,1.6470588235294117
2345,preference,1.6428571428571428
2346,biology,1.64
2347,equal,1.6363636363636365
2348,agbiome,1.6363636363636365
2349,review,1.631578947368421
2350,higher,1.631578947368421
2351,synglyco,1.6285714285714286
2352,effective,1.627906976744186
2353,borrowing,1.625
2354,discussion,1.625
2355,phylagen,1.625
2356,institution,1.625
2357,contract,1.625
2358,definition,1.625
2359,favorable,1.625
2360,principal,1.6153846153846154
2361,ordinary,1.6153846153846154
2362,effect,1.6097560975609757
2363,exercised,1.608695652173913
2364,escrow,1.6083333333333334
2365,securities,1.6071428571428572
2366,affect,1.6056338028169015
2367,disposition,1.6
2368,resulted,1.6
2369,execution,1.6
2370,ceased,1.6
2371,accumulated,1.6
2372,xenio,1.6
2373,difficult,1.5952380952380953
2374,security,1.589101620029455
2375,permitted,1.588235294117647
2376,nature,1.5833333333333333
2377,carrying,1.5789473684210527
2378,life,1.5777777777777777
2379,generally,1.576271186440678
2380,sold,1.574468085106383
2381,provide,1.5728155339805825
2382,located,1.5714285714285714
2383,iii,1.5714285714285714
2384,property,1.5714285714285714
2385,light,1.5714285714285714
2386,goal,1.5714285714285714
2387,expenses,1.5714285714285714
2388,calculate,1.5714285714285714
2389,guidance,1.5689655172413792
2390,table,1.5689655172413792
2391,july,1.564516129032258
2392,contingent,1.5625
2393,amended,1.5625
2394,source,1.5555555555555556
2395,maturity,1.5555555555555556
2396,approval,1.5555555555555556
2397,added,1.5555555555555556
2398,transferred,1.5555555555555556
2399,million,1.5555555555555556
2400,nanoscale,1.5555555555555556
2401,success,1.5555555555555556
2402,input,1.554054054054054
2403,time,1.5538461538461539
2404,summary,1.5476190476190477
2405,valued,1.546875
2406,acquiring,1.5454545454545454
2407,opportunity,1.5384615384615385
2408,presentation,1.5238095238095237
2409,technology,1.5192307692307692
2410,date,1.5185185185185186
2411,limited,1.5185185185185186
2412,reported,1.5116279069767442
2413,gaap,1.5
2414,responsible,1.5
2415,landlord,1.5
2416,dollar,1.5
2417,simplifying,1.5
2418,annum,1.5
2419,calculated,1.5
2420,circumstance,1.5
2421,default,1.5
2422,registration,1.5
2423,prospect,1.5
2424,profitability,1.5
2425,area,1.5
2426,decade,1.5
2427,building,1.5
2428,realizing,1.5
2429,inherently,1.5
2430,recognize,1.5
2431,critical,1.5
2432,support,1.5
2433,receivable,1.5
2434,principle,1.5
2435,warrants,1.5
2436,targeting,1.5
2437,reflected,1.5
2438,longer,1.5
2439,length,1.5
2440,reflect,1.4878048780487805
2441,satisfy,1.48
2442,meet,1.4761904761904763
2443,share,1.4743202416918428
2444,liabilities,1.4705882352941178
2445,comprised,1.46875
2446,raised,1.4615384615384615
2447,short,1.4615384615384615
2448,liability,1.4592592592592593
2449,identify,1.4545454545454546
2450,dilution,1.4545454545454546
2451,adjustment,1.4516129032258065
2452,disclosure,1.4482758620689655
2453,deemed,1.4444444444444444
2454,withheld,1.4444444444444444
2455,impact,1.4421052631578948
2456,percent,1.441527446300716
2457,ownership,1.4406779661016949
2458,result,1.4394618834080717
2459,transaction,1.4387096774193548
2460,record,1.4375
2461,recorded,1.4318181818181819
2462,fair,1.4307692307692308
2463,footnote,1.4285714285714286
2464,amortized,1.4285714285714286
2465,entity,1.4230769230769231
2466,set,1.4210526315789473
2467,structured,1.4210526315789473
2468,director,1.4181818181818182
2469,successful,1.4166666666666667
2470,money,1.4166666666666667
2471,investing,1.4166666666666667
2472,investments,1.4158075601374571
2473,ric,1.4090909090909092
2474,shareholder,1.4074074074074074
2475,restriction,1.4038461538461537
2476,directors,1.403361344537815
2477,ipo,1.4
2478,measurement,1.4
2479,measure,1.4
2480,distribute,1.4
2481,orig,1.4
2482,kovio,1.4
2483,materially,1.4
2484,interome,1.4
2485,reason,1.4
2486,monetize,1.4
2487,analysis,1.3888888888888888
2488,change,1.3873239436619718
2489,operation,1.3858267716535433
2490,bdc,1.3846153846153846
2491,series,1.3829787234042554
2492,focus,1.3793103448275863
2493,code,1.3783783783783783
2494,manner,1.375
2495,lesser,1.375
2496,access,1.375
2497,representation,1.375
2498,majority,1.375
2499,point,1.375
2500,assets,1.3728813559322033
2501,repurchase,1.3714285714285714
2502,class,1.3703703703703705
2503,percentage,1.3636363636363635
2504,abatement,1.3571428571428572
2505,regulation,1.3529411764705883
2506,consideration,1.35
2507,january,1.3461538461538463
2508,august,1.3428571428571427
2509,recognized,1.34
2510,included,1.3372093023255813
2511,seat,1.3333333333333333
2512,judgment,1.3333333333333333
2513,equipment,1.3333333333333333
2514,largest,1.3333333333333333
2515,completed,1.3333333333333333
2516,otisville,1.3333333333333333
2517,announced,1.3333333333333333
2518,agreed,1.3333333333333333
2519,commonly,1.3333333333333333
2520,applied,1.3333333333333333
2521,amends,1.3333333333333333
2522,customers,1.3333333333333333
2523,clearance,1.3333333333333333
2524,collaboration,1.3333333333333333
2525,alzheimer,1.3333333333333333
2526,quarter,1.3286713286713288
2527,conversion,1.3243243243243243
2528,purchase,1.3098591549295775
2529,contingencies,1.3076923076923077
2530,timing,1.3076923076923077
2531,october,1.3076923076923077
2532,increase,1.3061889250814331
2533,trade,1.303030303030303
2534,assignment,1.3
2535,advantage,1.3
2536,commission,1.3
2537,past,1.3
2538,hold,1.2941176470588236
2539,measured,1.2941176470588236
2540,december,1.2865168539325842
2541,achieved,1.2857142857142858
2542,prospectively,1.2857142857142858
2543,history,1.2857142857142858
2544,options,1.2857142857142858
2545,exercisable,1.2857142857142858
2546,pipeline,1.2857142857142858
2547,maturing,1.2857142857142858
2548,sell,1.2826086956521738
2549,observable,1.2777777777777777
2550,concern,1.2777777777777777
2551,difference,1.2745098039215685
2552,considered,1.2727272727272727
2553,defined,1.2692307692307692
2554,elected,1.2692307692307692
2555,repayment,1.2553191489361701
2556,enterprise,1.25
2557,driven,1.25
2558,allocation,1.25
2559,section,1.2456140350877194
2560,make,1.2424242424242424
2561,drawdown,1.2380952380952381
2562,derive,1.2325581395348837
2563,participate,1.2307692307692308
2564,maintain,1.2307692307692308
2565,operations,1.2295081967213115
2566,control,1.2222222222222223
2567,letter,1.2222222222222223
2568,issue,1.2222222222222223
2569,sale,1.2175
2570,important,1.2142857142857142
2571,provided,1.2105263157894737
2572,board,1.2034883720930232
2573,earnings,1.2
2574,creditor,1.2
2575,situation,1.2
2576,decrease,1.1993865030674846
2577,november,1.1935483870967742
2578,indirectly,1.1875
2579,results,1.1818181818181819
2580,grant,1.1785714285714286
2581,hzo,1.1785714285714286
2582,warrant,1.1724137931034482
2583,transfer,1.1724137931034482
2584,calculation,1.1666666666666667
2585,advance,1.1666666666666667
2586,assessment,1.1666666666666667
2587,commercialization,1.1666666666666667
2588,shift,1.1666666666666667
2589,form,1.1639344262295082
2590,metabolon,1.16
2591,april,1.1590909090909092
2592,require,1.15625
2593,range,1.1538461538461537
2594,invest,1.153061224489796
2595,ability,1.1470588235294117
2596,expect,1.1470588235294117
2597,accounted,1.1428571428571428
2598,nanosys,1.1428571428571428
2599,opgen,1.1391304347826088
2600,determined,1.1382978723404256
2601,subject,1.13125
2602,end,1.1282051282051282
2603,facilitate,1.125
2604,acquired,1.1176470588235294
2605,number,1.1176470588235294
2606,volatile,1.1153846153846154
2607,acquire,1.1142857142857143
2608,effort,1.1111111111111112
2609,ipos,1.1111111111111112
2610,close,1.105263157894737
2611,losses,1.1
2612,stated,1.0909090909090908
2613,forward,1.0909090909090908
2614,continue,1.0897435897435896
2615,shut,1.0869565217391304
2616,nantero,1.08
2617,reduce,1.0769230769230769
2618,follow,1.0746268656716418
2619,portion,1.0704225352112675
2620,extent,1.069767441860465
2621,acquisition,1.0666666666666667
2622,distributed,1.0666666666666667
2623,echopixel,1.0666666666666667
2624,canon,1.0588235294117647
2625,carried,1.0454545454545454
2626,compared,1.0440251572327044
2627,apply,1.0434782608695652
2628,type,1.0263157894736843
2629,opinion,1.0
2630,operate,1.0
2631,accordance,1.0
2632,condensed,1.0
2633,omitted,1.0
2634,conformity,1.0
2635,read,1.0
2636,conjunction,1.0
2637,page,1.0
2638,description,1.0
2639,seek,1.0
2640,efficiency,1.0
2641,computing,1.0
2642,instrument,1.0
2643,pledged,1.0
2644,collateral,1.0
2645,ascribed,1.0
2646,canada,1.0
2647,prosep,1.0
2648,reorganized,1.0
2649,lock,1.0
2650,restricts,1.0
2651,repaid,1.0
2652,minus,1.0
2653,achievement,1.0
2654,cancel,1.0
2655,impossible,1.0
2656,achieve,1.0
2657,spin,1.0
2658,retained,1.0
2659,filed,1.0
2660,assurance,1.0
2661,determination,1.0
2662,determine,1.0
2663,direction,1.0
2664,ensuring,1.0
2665,recommendation,1.0
2666,assigned,1.0
2667,liquidated,1.0
2668,prepared,1.0
2669,communicated,1.0
2670,measurements,1.0
2671,terminology,1.0
2672,utilized,1.0
2673,progress,1.0
2674,selection,1.0
2675,significance,1.0
2676,relevance,1.0
2677,deriving,1.0
2678,element,1.0
2679,directly,1.0
2680,instance,1.0
2681,classified,1.0
2682,indication,1.0
2683,ebitda,1.0
2684,proportion,1.0
2685,valuing,1.0
2686,research,1.0
2687,filing,1.0
2688,hour,1.0
2689,sundays,1.0
2690,holiday,1.0
2691,accuracy,1.0
2692,preparing,1.0
2693,highlight,1.0
2694,fixture,1.0
2695,reviewed,1.0
2696,responsibility,1.0
2697,specializes,1.0
2698,amp,1.0
2699,taxed,1.0
2700,subchapter,1.0
2701,instruction,1.0
2702,article,1.0
2703,preparation,1.0
2704,consolidate,1.0
2705,eliminated,1.0
2706,reclassified,1.0
2707,conform,1.0
2708,estimates,1.0
2709,amgen,1.0
2710,released,1.0
2711,connection,1.0
2712,capitalized,1.0
2713,furniture,1.0
2714,reduction,1.0
2715,accretion,1.0
2716,recoverable,1.0
2717,reversed,1.0
2718,accreted,1.0
2719,intention,1.0
2720,expensing,1.0
2721,intends,1.0
2722,qualify,1.0
2723,revised,1.0
2724,broadway,1.0
2725,behalf,1.0
2726,depreciated,1.0
2727,california,1.0
2728,disposed,1.0
2729,computed,1.0
2730,intend,1.0
2731,penalty,1.0
2732,maintained,1.0
2733,translated,1.0
2734,isolate,1.0
2735,arises,1.0
2736,exceed,1.0
2737,anticipated,1.0
2738,uncertainties,1.0
2739,restrict,1.0
2740,provision,1.0
2741,rebalance,1.0
2742,rest,1.0
2743,vulnerable,1.0
2744,unrelated,1.0
2745,arrears,1.0
2746,prepay,1.0
2747,affirmative,1.0
2748,limitation,1.0
2749,maintenance,1.0
2750,lien,1.0
2751,incurrence,1.0
2752,establishing,1.0
2753,compliance,1.0
2754,develop,1.0
2755,marketability,1.0
2756,unable,1.0
2757,ass,1.0
2758,evaluation,1.0
2759,outcome,1.0
2760,entitled,1.0
2761,case,1.0
2762,failing,1.0
2763,component,1.0
2764,sales,1.0
2765,qualification,1.0
2766,administer,1.0
2767,retiree,1.0
2768,spouse,1.0
2769,retirement,1.0
2770,age,1.0
2771,grandfathered,1.0
2772,respect,1.0
2773,cover,1.0
2774,delivered,1.0
2775,recipient,1.0
2776,represented,1.0
2777,reducing,1.0
2778,treated,1.0
2779,rics,1.0
2780,retain,1.0
2781,fail,1.0
2782,furnishing,1.0
2783,exploitation,1.0
2784,process,1.0
2785,addition,1.0
2786,qualified,1.0
2787,action,1.0
2788,ensure,1.0
2789,computation,1.0
2790,dilutive,1.0
2791,contribute,1.0
2792,withdrawal,1.0
2793,promuc,1.0
2794,annualized,1.0
2795,projection,1.0
2796,variation,1.0
2797,word,1.0
2798,intended,1.0
2799,relationship,1.0
2800,dependence,1.0
2801,objective,1.0
2802,adequacy,1.0
2803,monetization,1.0
2804,guarantee,1.0
2805,predict,1.0
2806,expressed,1.0
2807,forecasted,1.0
2808,impair,1.0
2809,contraction,1.0
2810,inability,1.0
2811,elect,1.0
2812,leverage,1.0
2813,prove,1.0
2814,inaccurate,1.0
2815,originate,1.0
2816,margin,1.0
2817,availability,1.0
2818,inclusion,1.0
2819,regarded,1.0
2820,background,1.0
2821,incorporated,1.0
2822,divested,1.0
2823,sections,1.0
2824,microscale,1.0
2825,overlap,1.0
2826,intersecting,1.0
2827,mathematics,1.0
2828,nanotechnology,1.0
2829,microtechnology,1.0
2830,observed,1.0
2831,leveraging,1.0
2832,execute,1.0
2833,trend,1.0
2834,recently,1.0
2835,excess,1.0
2836,built,1.0
2837,leader,1.0
2838,internet,1.0
2839,positioned,1.0
2840,size,1.0
2841,disconnect,1.0
2842,initiated,1.0
2843,implemented,1.0
2844,discontinued,1.0
2845,inaccessible,1.0
2846,organize,1.0
2847,realizations,1.0
2848,solazyme,1.0
2849,february,1.0
2850,stockholder,1.0
2851,dissolution,1.0
2852,consumer,1.0
2853,opgnw,1.0
2854,acceleration,1.0
2855,bring,1.0
2856,begin,1.0
2857,advisor,1.0
2858,attempt,1.0
2859,pursue,1.0
2860,tangible,1.0
2861,acceptance,1.0
2862,intent,1.0
2863,quality,1.0
2864,stronger,1.0
2865,liquidating,1.0
2866,nanoterra,1.0
2867,ultora,1.0
2868,shown,1.0
2869,figure,1.0
2870,transition,1.0
2871,backward,1.0
2872,accompanied,1.0
2873,implication,1.0
2874,studying,1.0
2875,evident,1.0
2876,step,1.0
2877,involvement,1.0
2878,membership,1.0
2879,observer,1.0
2880,uplisting,1.0
2881,formation,1.0
2882,banking,1.0
2883,knowledge,1.0
2884,running,1.0
2885,depicts,1.0
2886,noted,1.0
2887,confined,1.0
2888,addressing,1.0
2889,adjust,1.0
2890,magnitude,1.0
2891,grow,1.0
2892,decline,1.0
2893,sources,1.0
2894,undrawn,1.0
2895,examine,1.0
2896,assessing,1.0
2897,strength,1.0
2898,receivables,1.0
2899,add,1.0
2900,funding,1.0
2901,twenty,1.0
2902,compounded,1.0
2903,acute,1.0
2904,favor,1.0
2905,difficulty,1.0
2906,forced,1.0
2907,reaching,1.0
2908,translate,1.0
2909,finance,1.0
2910,illiquidity,1.0
2911,perception,1.0
2912,sum,1.0
2913,derivation,1.0
2914,referred,1.0
2915,backsolve,1.0
2916,honored,1.0
2917,parity,1.0
2918,relied,1.0
2919,defray,1.0
2920,unpredictable,1.0
2921,occurrence,1.0
2922,inflation,1.0
2923,quantity,1.0
2924,duration,1.0
2925,resignation,1.0
2926,expiration,1.0
2927,xradia,1.0
2928,exploration,1.0
2929,reinvestment,1.0
2930,establishes,1.0
2931,framework,1.0
2932,asc,1.0
2933,prioritizes,1.0
2934,transparency,1.0
2935,creditworthiness,1.0
2936,quantified,1.0
2937,subjectivity,1.0
2938,calculating,1.0
2939,assumes,1.0
2940,assumed,1.0
2941,adjusting,1.0
2942,changed,1.0
2943,statistical,1.0
2944,mortality,1.0
2945,estimating,1.0
2946,disposal,1.0
2947,obligated,1.0
2948,comply,1.0
2949,prohibition,1.0
2950,rule,1.0
2951,conducted,1.0
2952,maximum,1.0
2953,wellbeing,1.0
2954,ahead,1.0
2955,prevalent,1.0
2956,phenotypic,1.0
2957,shifted,1.0
2958,reorganization,1.0
2959,exist,1.0
2960,cancellation,1.0
2961,person,1.0
2962,release,1.0
2963,incurs,1.0
2964,deliver,1.0
2965,exceeds,1.0
2966,contracts,1.0
2967,customer,1.0
2968,depict,1.0
2969,approve,1.0
2970,evaluated,1.0
2971,terms,1.0
2972,disclose,1.0
2973,lessor,1.0
2974,simplify,1.0
2975,aspect,1.0
2976,reversal,1.0
2977,obtain,1.0
2978,grown,1.0
2979,pas,1.0
2980,performing,1.0
2981,opt,1.0
2982,identifying,1.0
2983,exert,1.0
2984,flexibility,1.0
2985,founded,1.0
2986,launched,1.0
2987,xmt,1.0
2988,faced,1.0
2989,challenge,1.0
2990,headwind,1.0
2991,returns,1.0
2992,seeking,1.0
2993,categorize,1.0
2994,predicated,1.0
2995,affected,1.0
2996,linked,1.0
2997,negotiation,1.0
2998,supportive,1.0
2999,occurring,1.0
3000,frequently,1.0
3001,dominated,1.0
3002,impacted,1.0
3003,oil,1.0
3004,exposure,1.0
3005,engagement,1.0
3006,expiring,1.0
3007,satisfied,1.0
3008,organizer,1.0
3009,deviate,1.0
3010,decide,1.0
3011,recapitalization,1.0
3012,counter,1.0
3013,modify,1.0
3014,finalize,1.0
3015,recover,1.0
3016,announcement,1.0
3017,department,1.0
